



National  
Comprehensive  
Cancer  
Network®

**NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)**

# **Small Cell Lung Cancer**

Version 2.2017 — September 15, 2016

**NCCN.org**

**Continue**



National  
Comprehensive  
Cancer  
Network®

# NCCN Guidelines Version 2.2017 Panel Members

## Small Cell Lung Cancer

[NCCN Guidelines Index](#)  
[Table of Contents](#)  
[Discussion](#)

\* **Gregory P. Kalemkerian, MD/Chair †**  
University of Michigan  
Comprehensive Cancer Center

\* **Billy W. Loo, Jr., MD, PhD/Vice Chair §**  
Stanford Cancer Institute

**Wallace Akerley, MD †**  
Huntsman Cancer Institute  
at the University of Utah

**Albert Attia, MD §**  
Vanderbilt-Ingram Cancer Center

**Laura QM Chow, MD †**  
Fred Hutchinson Cancer Research  
Center/Seattle Cancer Care Alliance

**Roy Decker, MD, PhD §**  
Yale Cancer Center/Smilow Cancer Hospital

**M. Chris Dobelbower, MD, PhD §**  
University of Alabama at Birmingham  
Comprehensive Cancer Center

**Afshin Dowlati, MD †**  
Case Comprehensive Cancer Center/  
University Hospitals Seidman Cancer  
Center and Cleveland Clinic Taussig  
Cancer Institute

**Robert J. Downey, MD ¶**  
Memorial Sloan Kettering Cancer Center

**Charles Florsheim**  
Patient Advocate

**Apar Kishor P. Ganti, MD †**  
Fred & Pamela Buffett Cancer Center

**John C. Grecula, MD §**  
The Ohio State University Comprehensive  
Cancer Center - James Cancer Hospital  
and Solove Research Institute

**Matthew A. Gubens, MD, MS †**  
UCSF Helen Diller Family  
Comprehensive Cancer Center

**Christine L. Hann, MD, PhD †**  
The Sidney Kimmel Comprehensive  
Cancer Center at Johns Hopkins

**James A. Hayman, MD, MBA §**  
University of Michigan  
Comprehensive Cancer Center

**Rebecca Suk Heist, MD, MPH †**  
Massachusetts General Hospital  
Cancer Center

**Marianna Koczywas, MD † ‡ P**  
City of Hope Comprehensive  
Cancer Center

**Ranee Mehra, MD †**  
Fox Chase Cancer Center

**Robert E. Merritt, MD ¶**  
The Ohio State University Comprehensive  
Cancer Center - James Cancer Hospital  
and Solove Research Institute

**Nisha Mohindra, MD †**  
Robert H. Lurie Comprehensive Cancer  
Center of Northwestern University

**Julian Molina, MD, PhD ‡ P**  
Mayo Clinic Cancer Center

**Cesar A. Moran, MD ≠**  
The University of Texas  
MD Anderson Cancer Center

**Daniel Morgensztern, MD †**  
Siteman Cancer Center at Barnes-  
Jewish Hospital and Washington  
University School of Medicine

**Saraswati Pokharel, MD ≠**  
Roswell Park Cancer Institute

**David C. Portnoy, MD ‡ †**  
The University of Tennessee  
Health Science Center

**Neal Ready, MD, PhD †**  
Duke Cancer Institute

**Chad Rusthoven, MD §**  
University of Colorado Cancer Center

**Charles C. Williams, Jr., MD †**  
Moffitt Cancer Center

### **NCCN**

**Karin G. Hoffmann, RN, CCM**  
**Miranda Hughes, PhD**

† Medical oncology  
¶ Surgery/Surgical oncology  
§ Radiation oncology  
‡ Hematology/Hematology oncology  
P Internal medicine  
≠ Pathology  
\*Discussion Section Writing Committee

[NCCN Guidelines Panel Disclosures](#)

**Continue**



### [NCCN Small Cell Lung Cancer Panel Members](#)

### [Summary of the Guidelines Updates](#)

#### Small Cell Lung Cancer:

- [Initial Evaluation and Staging \(SCL-1\)](#)
- [Limited Stage, Workup and Treatment \(SCL-2\)](#)
- [Extensive Stage, Initial Treatment \(SCL-4\)](#)
- [Response Assessment Following Initial Therapy \(SCL-5\)](#)
- [Surveillance \(SCL-5\)](#)
- [Progressive Disease: Subsequent Therapy and Palliative Therapy \(SCL-6\)](#)
- [Principles of Surgical Resection \(SCL-A\)](#)
- [Principles of Supportive Care \(SCL-B\)](#)
- [Principles of Systemic Therapy \(SCL-C\)](#)
- [Principles of Radiation Therapy \(SCL-D\)](#)

#### Lung Neuroendocrine Tumors:

- [Workup and Primary Treatment \(LNT-1\)](#)
  - ▶ Low-grade neuroendocrine carcinoma (typical carcinoid)
  - ▶ Intermediate-grade neuroendocrine carcinoma (atypical carcinoid)
  - ▶ High-grade neuroendocrine carcinoma (large-cell neuroendocrine carcinoma)
  - ▶ High-grade neuroendocrine carcinoma (small cell carcinoma)
  - ▶ Combined SCLC and NSCLC
- [Primary and Adjuvant Treatment \(LNT-2\)](#)
- [Principles of Systemic Therapy \(LNT-A\)](#)

### [Staging \(ST-1\)](#)

**Clinical Trials:** NCCN believes that the best management for any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

To find clinical trials online at NCCN Member Institutions, [click here: nccn.org/clinical\\_trials/physician.html](#).

**NCCN Categories of Evidence and Consensus:** All recommendations are category 2A unless otherwise specified.

See [NCCN Categories of Evidence and Consensus](#).

The NCCN Guidelines® are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representations or warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way. The NCCN Guidelines are copyrighted by National Comprehensive Cancer Network®. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2016.



# NCCN Guidelines Version 2.2017 Updates

## Small Cell Lung Cancer

Updates in Version 2.2017 of the NCCN Guidelines for Small Cell Lung Cancer from Version 1.2017 include:

### [MS-1](#)

The Discussion section has been updated to reflect the changes in the algorithm.

Updates in Version 1.2017 of the NCCN Guidelines for Small Cell Lung Cancer from Version 1.2016 include:

### [SCL-1](#)

#### • Initial evaluation

- ▶ Bullet 3 modified: “~~CBC with differential, platelets~~”
- ▶ Bullet 6 modified: “~~Chest/liver/adrenal CT with contrast whenever possible~~”
- ▶ Bullet 7 modified: “~~Brain MRI (preferred) or CT with contrast whenever possible~~” (Also for SCL-5)

### [SCL-2](#)

#### • Clinical stage T1-2, N0

- ▶ Pathway statement removed: PET-CT scan “(if not previously obtained)”
- ▶ Footnote removed: “PET-CT scan to identify distant disease and to guide mediastinal evaluation, if not previously done.”

### [SCL-3](#)

#### • Initial Treatment

- ▶ Clinical stage T1-2, N0; Pathologic mediastinal staging positive or medically inoperable or decision made not to pursue surgical resection: Recommendations combined with Limited stage in excess of T1-2, N0.
- ▶ Limited stage in excess of T1-2, N0, initial treatment option modified: “Systemic therapy ± RT (*concurrent or sequential*)”
- ▶ Footnote “m” added: “For patients receiving adjuvant therapy, response assessment should occur only after completion of initial therapy (SCL-5); do not repeat scans to assess response during adjuvant treatment.”
- ▶ Footnote “n” added: “For patients receiving systemic therapy + concurrent RT, response assessment should occur only after completion of initial therapy (SCL-5); do not repeat scans to assess response during initial treatment. For patients receiving systemic therapy alone or sequential systemic therapy followed by RT, response assessment by CT chest/liver/adrenal with contrast should occur after every 2 cycles of systemic therapy and at completion of therapy (SCL-5).”

### [SCL-4](#)

- Footnote “o” added: “For patients with asymptomatic brain metastases receiving systemic therapy before whole-brain RT, brain MRI (preferred) or CT with contrast should be repeated after every 2 cycles of systemic therapy and at completion of therapy (SCL-5).”
- Footnote “p” added: “During systemic therapy, response assessment by CT chest/liver/adrenal with contrast should occur after every 2–3 cycles of systemic therapy and at completion of therapy (SCL-5).”

### [SCL-5](#)

#### • Response Assessment Following Initial Therapy

- ▶ Bullet 2 modified: “~~Chest/liver/adrenal CT with contrast whenever possible~~”
- ▶ Bullet 3 modified: “~~Brain MRI (preferred) or CT with contrast whenever possible~~, if prophylactic cranial irradiation (PCI) to be given”
- ▶ Bullet removed: “Other imaging studies, to assess prior sites of involvement, as clinically indicated”
- ▶ Bullet 5 modified: “~~CBC, platelets~~”

• Adjuvant Treatment; Extensive disease: “PCI + thoracic RT” changed to “PCI ± thoracic RT.”

• Surveillance; Bullet 1, sub-bullet 1 modified: “At every visit: H&P, ~~CT chest imaging/liver/adrenal~~, bloodwork as clinically indicated”



Updates in Version 1.2017 of the NCCN Guidelines for Small Cell Lung Cancer from Version 1.2016 include:

### [SCL-6](#)

- Footnote “s” added: “A response assessment by CT chest/liver/adrenal with contrast should occur after every 2–3 cycles of systemic therapy.”

### [SCL-A](#)

- Reference “5” added: “Yang CE, Chan DY, Speicher PJ, et al. Role of adjuvant therapy in a population based cohort of patients with early-stage small-cell lung cancer. *J Clin Oncol* 2016;34:1057-1064.”

### [SCL-C 1 OF 3](#)

- Title modified: “Principles of ~~Chemotherapy~~ *Systemic Therapy*” (also applies to SCL-C 2 of 3 and SCL-C 3 of 3)
- Systemic therapy as primary therapy or adjuvant therapy; Extensive stage: Carboplatin and etoposide regimen moved from bullet 4 to bullet 1.
- Subsequent systemic therapy
  - ▶ The decision point of “relapse <2–3 mo, PS 0-2” versus “relapse >2–3 mo up to 6 mo” removed.
  - ▶ Category 1 removed from topotecan.
  - ▶ Ifosfamide removed as an option.
  - ▶ Nivolumab ± ipilimumab added as a treatment option as a category 2A.
  - ▶ Statement modified: “Consider dose reduction ~~versus growth factors in the poor performance status patient or growth factor support for patients with PS 2~~”

### [SCL-C 2 OF 3](#)

- Response Assessment section is new to the guideline (SCL-C 2 of 3).

### [SCL-D 2 of 3](#)

#### • Brain Metastases

- ▶ Bullet 1 modified: “Brain metastases should be treated with whole brain radiation therapy (WBRT) rather than stereotactic radiotherapy/radiosurgery (SRT/SRS) alone, because these patients tend to develop multiple CNS metastases. In patients who develop brain metastases after PCI, repeat WBRT may be considered in carefully selected patients. SRS may also be considered, especially if there has been a long-time interval from initial diagnosis to occurrence of brain metastases and there is no *uncontrolled* extracranial disease.”




# NCCN Guidelines Version 2.2017

## Small Cell Lung Cancer

### DIAGNOSIS

### INITIAL EVALUATION<sup>a</sup>

### STAGE



<sup>a</sup>If extensive stage is established, further staging evaluation is optional. However, brain imaging, MRI (preferred), or CT with contrast should be obtained in all patients.

<sup>b</sup>Brain MRI is more sensitive than CT for identifying brain metastases and is preferred over CT.

<sup>c</sup>If PET/CT is not available, bone scan may be used to identify metastases. Pathologic confirmation is recommended for lesions detected by PET/CT that alter stage.

**Note:** All recommendations are category 2A unless otherwise indicated.


**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 2.2017

## Small Cell Lung Cancer

**STAGE**                      **ADDITIONAL WORKUP**



<sup>d</sup>While most pleural effusions in patients with lung cancer are due to tumor, there are a few patients in whom multiple cytopathologic examinations of pleural fluid are negative for tumor and fluid is non-bloody and not an exudate. When these elements and clinical judgment dictate that the effusion is not related to the tumor, the effusion should be excluded as a staging element. Pericardial effusion is classified using the same criteria.

<sup>e</sup>Selection criteria include: nucleated red blood cells (RBCs) on peripheral blood smear, neutropenia, or thrombocytopenia suggestive of bone marrow infiltration.

<sup>f</sup>[See Principles of Surgical Resection \(SCL-A\).](#)

<sup>9</sup>Mediastinal staging procedures include mediastinoscopy, mediastinotomy, endobronchial or esophageal ultrasound-guided biopsy, and video-assisted thoracoscopy. If endoscopic lymph node biopsy is positive, additional mediastinal staging is not required.


<sup>h</sup>Pathologic mediastinal staging is not required if the patient is not a candidate for surgical resection or if non-surgical treatment is pursued.

**Note: All recommendations are category 2A unless otherwise indicated.**  
**Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**



# NCCN Guidelines Version 2.2017

## Small Cell Lung Cancer



<sup>f</sup>See Principles of Surgical Resection (SCL-A).

<sup>g</sup>Mediastinal staging procedures include mediastinoscopy, mediastinotomy, endobronchial or esophageal ultrasound-guided biopsy, and video-assisted thoracoscopy. If endoscopic lymph node biopsy is positive, additional mediastinal staging is not required.

<sup>i</sup>See Principles of Supportive Care (SCL-B).

<sup>j</sup>Select patients may be treated with systemic therapy/RT as an alternative to surgical resection.

<sup>k</sup>See Principles of Systemic Therapy (SCL-C).

<sup>l</sup>See Principles of Radiation Therapy (SCL-D).

<sup>m</sup>For patients receiving adjuvant therapy, response assessment should occur only after completion of initial therapy (SCL-5); do not repeat scans to assess response during adjuvant treatment.


<sup>n</sup>For patients receiving systemic therapy + concurrent RT, response assessment should occur only after completion of initial therapy (SCL-5); do not repeat scans to assess response during initial treatment. For patients receiving systemic therapy alone or sequential systemic therapy followed by RT, response assessment by CT chest/liver/adrenal with contrast should occur after every 2 cycles of systemic therapy and at completion of therapy (SCL-5).

**Note: All recommendations are category 2A unless otherwise indicated.**  
**Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**



# NCCN Guidelines Version 2.2017

## Small Cell Lung Cancer



<sup>i</sup>See Principles of Supportive Care (SCL-B).

<sup>k</sup>See Principles of Systemic Therapy (SCL-C).

<sup>l</sup>See Principles of Radiation Therapy (SCL-D).

<sup>o</sup>For patients with asymptomatic brain metastases receiving systemic therapy before whole-brain RT, brain MRI (preferred) or CT with contrast should be repeated after every 2 cycles of systemic therapy and at completion of therapy ([SCL-5](#)).

<sup>p</sup>During systemic therapy, response assessment by CT chest/liver/adrenal with contrast should occur after every 2–3 cycles of systemic therapy and at completion of therapy ([SCL-5](#)).

**Note: All recommendations are category 2A unless otherwise indicated.**  
**Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**




# NCCN Guidelines Version 2.2017

## Small Cell Lung Cancer

### RESPONSE ASSESSMENT FOLLOWING INITIAL THERAPY

- Chest x-ray (optional)
- Chest/liver/adrenal CT with contrast
- Brain MRI<sup>b</sup> (preferred) or CT with contrast, if prophylactic cranial irradiation (PCI) to be given
- CBC
- Electrolytes, LFTs, Ca, BUN, creatinine



### ADJUVANT TREATMENT

### SURVEILLANCE

After recovery from primary therapy:

- Oncology follow-up visits every 3–4 mo during y 1–2, every 6 mo during y 3–5, then annually
  - ▶ At every visit: H&P, CT chest/liver/adrenal, bloodwork as clinically indicated
- New pulmonary nodule should initiate workup for potential new primary
- Smoking cessation intervention, see the [NCCN Guidelines for Smoking Cessation](#)
- PET/CT is not recommended for routine follow-up

[For Relapse, see Subsequent Therapy \(SCL-6\)](#)

[See Subsequent Therapy/ Palliative Therapy \(SCL-6\)](#)

<sup>b</sup>Brain MRI is more sensitive than CT for identifying brain metastases and is preferred over CT.

<sup>l</sup>[See Principles of Radiation Therapy \(SCL-D\)](#).

<sup>q</sup>Not recommended in patients with poor performance status or impaired neurocognitive function.

<sup>r</sup>Sequential radiotherapy to thorax in selected patients with low-bulk metastatic disease and complete response (CR) or near CR after systemic therapy.


**Note: All recommendations are category 2A unless otherwise indicated.**  
**Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**



# NCCN Guidelines Version 2.2017

## Small Cell Lung Cancer

**PROGRESSIVE DISEASE      SUBSEQUENT THERAPY/PALLIATIVE THERAPY**



<sup>k</sup>See Principles of Systemic Therapy (SCL-C).

<sup>l</sup>See Principles of Radiation Therapy (SCL-D).

<sup>s</sup>Response assessment by CT chest/liver/adrenal with contrast should occur after every 2–3 cycles of systemic therapy.

**Note: All recommendations are category 2A unless otherwise indicated.**  
**Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**



### PRINCIPLES OF SURGICAL RESECTION

- Stage I SCLC is diagnosed in less than 5% of patients with SCLC.
- Patients with disease in excess of T1-2, N0 do not benefit from surgery.<sup>1</sup>
- Patients with SCLC that is clinical stage I (T1-2, N0) after standard staging evaluation (including CT of the chest and upper abdomen, brain imaging, and PET/CT imaging) may be considered for surgical resection.
  - ▶ Prior to resection, all patients should undergo mediastinoscopy or other surgical mediastinal staging to rule out occult nodal disease. This may also include an endoscopic staging procedure.
  - ▶ Patients who undergo complete resection (preferably by a lobectomy with either mediastinal nodal dissection or sampling) should be treated with postoperative systemic therapy. Patients without nodal metastases should be treated with systemic therapy alone. Patients with nodal metastases should be treated with postoperative concurrent systemic therapy and mediastinal radiation therapy (RT).
- Because PCI can improve both disease-free and overall survival in patients with SCLC who have complete or partial response, PCI is recommended after adjuvant systemic therapy in patients who have undergone a complete resection.<sup>2</sup> PCI is not recommended in patients with poor performance status or impaired neurocognitive functioning.<sup>3,4,5</sup>

<sup>1</sup>Lad T, Piantadosi S, Thomas P, et al. A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. *Chest* 1994;106:320S-3S.

<sup>2</sup>Auperin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. *N Engl J Med* 1999;341:476-84.

<sup>3</sup>Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. *N Engl J Med* 2007;357:664-672.

<sup>4</sup>Le Péchoux C, Dunant A, Senan S, et al. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy. *Lancet Oncol* 2009;10(5):467-474.

<sup>5</sup>Yang CE, Chan DY, Speicher PJ, et al. Role of adjuvant therapy in a population based cohort of patients with early-stage small-cell lung cancer. *J Clin Oncol* 2016;34:1057-1064.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



### PRINCIPLES OF SUPPORTIVE CARE

- **Smoking cessation advice, counseling, and pharmacotherapy**
  - ▶ **Use the 5 A's Framework: Ask, Advise, Assess, Assist, Arrange** (<http://www.ahrq.gov/clinic/tobacco/5steps.htm>)
  - ▶ [See NCCN Guidelines for Smoking Cessation](#)
- **Granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) is not recommended during concurrent systemic therapy plus radiotherapy (category 1 for not using GM-CSF).<sup>1</sup>**
- **Syndrome of inappropriate antidiuretic hormone**
  - ▶ **Fluid restriction**
  - ▶ **Saline infusion for symptomatic patients**
  - ▶ **Antineoplastic therapy**
  - ▶ **Demeclocycline**
  - ▶ **Vasopressin receptor inhibitors (conivaptan, tolvaptan)**
- **Cushing's syndrome**
  - ▶ **Consider ketoconazole. If not effective, consider metyrapone.**
  - ▶ **Try to control before initiation of antineoplastic therapy**
- **Leptomeningeal disease:** [See NCCN Guidelines for Carcinomatous/Lymphomatous Meningitis](#)
- **Pain management:** [See NCCN Guidelines for Adult Cancer Pain](#)
- **Nausea/vomiting:** [See NCCN Guidelines for Antiemesis](#)
- **Psychosocial distress:** [See NCCN Guidelines for Distress Management](#)
- [See NCCN Guidelines for Palliative Care](#) as indicated

<sup>1</sup>Bunn PA, Crowley J, Kelly K, et al. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. *J Clin Oncol* 1995;13:1632-1641.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**PRINCIPLES OF SYSTEMIC THERAPY\* (1 of 3)****Systemic therapy as primary or adjuvant therapy:**

- **Limited stage (maximum of 4–6 cycles):**
  - ▶ Cisplatin 60 mg/m<sup>2</sup> day 1 and etoposide 120 mg/m<sup>2</sup> days 1, 2, 3<sup>1</sup>
  - ▶ Cisplatin 80 mg/m<sup>2</sup> day 1 and etoposide 100 mg/m<sup>2</sup> days 1, 2, 3<sup>2</sup>
  - ▶ Carboplatin AUC 5–6 day 1 and etoposide 100 mg/m<sup>2</sup> days 1, 2, 3<sup>3</sup>
  - ▶ During systemic therapy + RT, cisplatin/etoposide is recommended (category 1).
  - ▶ The use of myeloid growth factors is not recommended during concurrent systemic therapy plus radiotherapy (category 1 for not using GM-CSF).<sup>\*\*</sup>
- **Extensive stage (maximum of 4–6 cycles):**
  - ▶ Carboplatin AUC 5–6 day 1 and etoposide 100 mg/m<sup>2</sup> days 1, 2, 3<sup>4</sup>
  - ▶ Cisplatin 75 mg/m<sup>2</sup> day 1 and etoposide 100 mg/m<sup>2</sup> days 1, 2, 3<sup>5</sup>
  - ▶ Cisplatin 80 mg/m<sup>2</sup> day 1 and etoposide 80 mg/m<sup>2</sup> days 1, 2, 3<sup>6</sup>
  - ▶ Cisplatin 25 mg/m<sup>2</sup> days 1, 2, 3 and etoposide 100 mg/m<sup>2</sup> days 1, 2, 3<sup>7</sup>
  - ▶ Carboplatin AUC 5 day 1 and irinotecan 50 mg/m<sup>2</sup> days 1, 8, 15<sup>8</sup>
  - ▶ Cisplatin 60 mg/m<sup>2</sup> day 1 and irinotecan 60 mg/m<sup>2</sup> days 1, 8, 15<sup>9</sup>
  - ▶ Cisplatin 30 mg/m<sup>2</sup> and irinotecan 65 mg/m<sup>2</sup> days 1, 8<sup>10</sup>

**Subsequent systemic therapy:**

- **Clinical trial preferred.**
  - **Relapse ≤6 mo, PS 0-2:**
    - ▶ topotecan PO or IV<sup>11-13</sup>
    - ▶ irinotecan<sup>14</sup>
    - ▶ paclitaxel<sup>15,16</sup>
    - ▶ docetaxel<sup>17</sup>
    - ▶ temozolomide<sup>18,19</sup>
    - ▶ nivolumab ± ipilimumab<sup>20</sup>
    - ▶ vinorelbine<sup>21,22</sup>
    - ▶ oral etoposide<sup>23,24</sup>
    - ▶ gemcitabine<sup>25,26</sup>
    - ▶ cyclophosphamide/doxorubicin/vincristine (CAV)<sup>11</sup>
    - ▶ bendamustine (category 2B)<sup>27</sup>
  - **Relapse >6 mo: original regimen<sup>28,29</sup>**
- Consider dose reduction or growth factor support for patients with PS 2

[Response Assessment SCL-C 2 of 3](#)[References on SCL-C 3 of 3](#)

\*The regimens included are representative of the more commonly used regimens for small cell lung cancer. Other regimens may be acceptable.

\*\*Bunn PA, Crowley J, Kelly K, et al. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. *J Clin Oncol* 1995;13:1632-1641.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



### PRINCIPLES OF SYSTEMIC THERAPY (2 of 3)

#### Response assessment

##### • Limited-stage

- ▶ For patients receiving adjuvant therapy, response assessment should occur only after completion of initial therapy; do not repeat scans to assess response during adjuvant treatment.
- ▶ For patients receiving systemic therapy + concurrent RT, response assessment should occur only after completion of initial therapy; do not repeat scans to assess response during initial treatment.
- ▶ For patients receiving systemic therapy alone or sequential systemic therapy followed by RT, response assessment by CT chest/liver/adrenal with contrast should occur after every 2 cycles of systemic therapy and at completion of therapy.

##### • Extensive-stage

- ▶ During systemic therapy, response assessment by CT chest/liver/adrenal with contrast should occur after every 2–3 cycles of systemic therapy and at completion of therapy.
- ▶ For patients with asymptomatic brain metastases receiving systemic therapy before whole-brain RT, brain MRI (preferred) or CT with contrast should be repeated after every 2 cycles of systemic therapy and at completion of therapy.

##### • Subsequent systemic therapy

- ▶ Response assessment by CT chest/liver/adrenal with contrast should occur after every 2–3 cycles of systemic therapy.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**PRINCIPLES OF SYSTEMIC THERAPY (3 of 3)****References**

- <sup>1</sup>Turrisi AT 3rd, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. *N Engl J Med* 1999;340(4):265-271.
- <sup>2</sup>Saito H, Takada Y, Ichinose Y, et al. Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902. *J Clin Oncol* 2006;24(33): 5247-5252.
- <sup>3</sup>Skarlos DV, Samantas E, Briassoulis E, et al. Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG). *Ann Oncol* 2001;12(9):1231-1238.
- <sup>4</sup>Okamoto H, Watanabe K, Nishiwaki Y, et al. Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small cell lung cancer. *J Clin Oncol* 1999;17(11):3540-3545.
- <sup>5</sup>Spigel DR, Townley PM, Waterhouse DM, et al. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. *J Clin Oncol* 2011;29:2215-2222.
- <sup>6</sup>Niell HB, Herndon JE, Miller AA, et al. Randomized phase III Intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte-colony stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B trial 9732. *J Clin Oncol* 2005;23:3752-3759.
- <sup>7</sup>Evans WK, Shepherd FA, Feld R, et al. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. *J Clin Oncol* 1985;3(11):1471-1477.
- <sup>8</sup>Schmittl A, Fischer von Weikersthal L, Sebastian M, et al. A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer. *Ann Oncol* 2006;17:663-667.
- <sup>9</sup>Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. *N Engl J Med* 2002;346(2): 85-91.
- <sup>10</sup>Hanna N, Bunn Jr. PA, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. *J Clin Oncol* 2006;24(13):2038-2043.
- <sup>11</sup>von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. *J Clin Oncol* 1999;17(2):658-667.
- <sup>12</sup>O'Brien ME, Ciuleanu TE, Tsekou H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. *J Clin Oncol* 2006;24(34):5441-5447.
- <sup>13</sup>Eckardt JR, von Pawel J, Pujol JL, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. *J Clin Oncol* 2007;25(15):2086-2092.
- <sup>14</sup>Masuda N, Fukuoka M, Kusunoki Y, et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. *J Clin Oncol* 1992; 10:1225-1229.
- <sup>15</sup>Smit EF, Fokkema E, Biesma B, et al. A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. *Br J Cancer* 1998; 77:347-351.
- <sup>16</sup>Yamamoto N, Tsurutani J, Yoshimura N, et al. Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer. *Anticancer Res* 2006; 26:777-781.
- <sup>17</sup>Smyth JF, Smith IE, Sessa C, et al. Activity of docetaxel (Taxotere) in small cell lung cancer. *Eur J Cancer* 1994; 30A:1058-1060.
- <sup>18</sup>Pietanza MC, Kadota K, Huberman K, et al. Phase II trial of temozolomide with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker. *Clin Cancer Res* 2012;18:1138-1145.
- <sup>19</sup>Zauderer MG, Drilon A, Kadota K, et al. Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase. *Lung Cancer* 2014;86:237-240.
- <sup>20</sup>Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (Checkmate 032): a multicentre, open-label phase 1/2 trial. *Lancet Oncol* 2016;17:883-895.
- <sup>21</sup>Jassem J, Karnicka-Mlodkowska H, van Pottelsberghe C, et al. Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. *Eur J Cancer* 1993; 29A:1720-1722.
- <sup>22</sup>Furuse K, Kuboa K, Kawahara M, et al. Phase II study of vinorelbine in heavily previously treated small cell lung cancer. *Oncology* 1996; 53:169-172.
- <sup>23</sup>Einhorn LH, Pennington K, McClean J. Phase II trial of daily oral VP-16 in refractory small cell lung cancer. *Semin Oncol* 1990; 17:32-35.
- <sup>24</sup>Johnson DH, Greco FA, Strupp J, et al. Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial. *J Clin Oncol* 1990; 8:1613-1617.
- <sup>25</sup>Van der Lee I, Smit EF, van Putten JW, et al. Single-agent gemcitabine in patients with resistant small-cell lung cancer. *Ann Oncol* 2001;12:557-561.
- <sup>26</sup>Masters GA, Declerck L, Blanke C, et al. Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer. *J Clin Oncol* 2003;21:1550-1555.
- <sup>27</sup>Lammers PE, Shyr Y, Li CI, et al. Phase II study of bendamustine in relapsed chemotherapy sensitive or resistant small-cell lung cancer. *J Thorac Oncol* 2014;9:559-562.
- <sup>28</sup>Postmus PE, Berendsen HH, van Zandwijk N, et al. Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. *Eur J Cancer Clin Oncol* 1987;23:1409-1411.
- <sup>29</sup>Giaccone G, Ferrati P, Donadio M, et al. Reinduction chemotherapy in small cell lung cancer. *Eur J Cancer Clin Oncol* 1987;23:1697-1699.

**Note: All recommendations are category 2A unless otherwise indicated.****Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**

**PRINCIPLES OF RADIATION THERAPY****General Principles:**

- **General principles of RT for lung cancer—including commonly used abbreviations; standards for clinical and technologic expertise and quality assurance; and principles of RT simulation, planning, and delivery—are provided in the NCCN Guidelines for Non-Small Cell Lung Cancer (see NSCL-B) and are applicable to RT for SCLC.**
- **RT has a potential role in all stages of SCLC, as part of either definitive or palliative therapy. Radiation oncology input, as part of a multidisciplinary evaluation or discussion, should be provided for all patients early in the determination of the treatment strategy.**
- **To maximize tumor control and to minimize treatment toxicity, critical components of modern RT include appropriate simulation, accurate target definition, conformal RT planning, and ensuring accurate delivery of the planned treatment. A minimum standard is CT-planned 3D conformal RT. Multiple fields should be used, with all fields treated each day.**
- **Use of more advanced technologies is appropriate when needed to deliver adequate tumor doses while respecting normal tissue dose constraints. Such technologies include (but are not limited to) 4D-CT and/or PET/CT simulation, IMRT/VMAT, IGRT, and motion management strategies. Quality assurance measures are essential and are covered in the NSCLC guidelines (see NSCL-B).**
- **Useful references include the ACR Appropriateness Criteria at: <http://www.acr.org/quality-safety/appropriateness-criteria>**

**Limited Stage:**

- **Timing: RT concurrent with systemic therapy is standard and preferred to sequential chemo/RT.<sup>1</sup> RT should start early, with cycle 1 or 2 of systemic therapy (category 1).<sup>2</sup> A shorter time from the start of any therapy to the end of RT (SER) is significantly associated with improved survival.<sup>3</sup>**
- **Target definition: RT target volumes should be defined based on the pretreatment PET scan and CT scan obtained at the time of radiotherapy planning. PET/CT should be obtained, preferably within 4 weeks and no more than 8 weeks, before treatment. Ideally, PET/CT should be obtained in the treatment position.**
- **Historically, clinically uninvolved mediastinal nodes have been included in the RT target volume, whereas uninvolved supraclavicular nodes generally have not been included. Consensus on elective nodal irradiation (ENI) is evolving.<sup>4</sup> Several more modern series, both retrospective and prospective, suggest that omission of ENI results in low rates of isolated nodal recurrences (0%–11%, most <5%), particularly when incorporating PET staging/target definition (1.7%–3%).<sup>5-10</sup> ENI has been omitted in current prospective clinical trials (including CALGB 30610/RTOG 0538 and the EORTC 08072 [CONVERT] trial).**
- **In patients who start systemic therapy before RT, the gross tumor volume (GTV) can be limited to the post-induction systemic therapy volume to avoid excessive toxicity. Initially involved nodal regions (but not their entire pre-systemic therapy volume) should be covered.<sup>7,11</sup>**
- **Dose and schedule: For limited-stage SCLC, the optimal dose and schedule of RT have not been established; 45 Gy in 3 weeks (1.5 Gy twice daily [BID]) is superior (category 1) to 45 Gy in 5 weeks (1.8 Gy daily).<sup>12,13</sup> When BID fractionation is used, there should be at least a 6-hour inter-fraction interval to allow for repair of normal tissue. If using once-daily RT, higher doses of 60–70 Gy should be used.<sup>14-17</sup> The current randomized trial CALGB 30610/RTOG 0538 is comparing the standard arm of 45 Gy (BID) in 3 weeks to 70 Gy in 7 weeks; accrual to an experimental concomitant boost arm<sup>18</sup> has closed.**

[See Extensive Stage, Normal Tissue Dose Constraints, Prophylactic Cranial Irradiation, Brain Metastases on SCL-D 2 of 3](#)

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**PRINCIPLES OF RADIATION THERAPY****Extensive Stage:**

- Consolidative thoracic RT is beneficial for selected patients with extensive-stage SCLC that responds to systemic therapy. Studies have demonstrated that consolidative thoracic RT is well tolerated, results in fewer symptomatic chest recurrences, and improves long-term survival in some patients.<sup>19,20</sup> The Dutch CREST randomized trial of modest-dose thoracic RT in patients with extensive stage SCLC that responded to systemic therapy demonstrated significantly improved two-year overall survival and six-month progression-free survival, although the protocol-defined primary endpoint of one-year overall survival was not significantly improved.<sup>21</sup>

**Normal Tissue Dose Constraints:**

- Normal tissue dose constraints depend on tumor size and location. For similar RT prescription doses, the normal tissue constraints used for NSCLC are appropriate ([see NSCL-B](#)).
- When administering accelerated RT schedules (eg, BID) or lower total RT doses (eg, 45 Gy), more conservative constraints should be used. When using accelerated schedules (eg, 3–5 weeks), the spinal cord constraints from the CALGB 30610/RTOG 0538 protocol should be used as a guide: ie, the maximum spinal cord dose should be limited to ≤41 Gy (including scatter irradiation) for a prescription of 45 Gy BID in 3 weeks and limited to ≤50 Gy for more protracted schedules.

**Prophylactic Cranial Irradiation (PCI):**

- In patients with limited-stage SCLC who have a good response to initial therapy, PCI decreases brain metastases and increases overall survival (category 1).<sup>22,23</sup> In patients with extensive-stage SCLC that has responded to systemic therapy, PCI decreases brain metastases. However, while a randomized trial conducted by the EORTC found improved overall survival with PCI,<sup>24</sup> preliminary results from a Japanese randomized trial found no improved overall survival in patients who had MRI to confirm absence of brain metastases.<sup>25</sup> In patients not receiving PCI, surveillance for metastases by brain imaging should be considered.
- The preferred dose for PCI to the whole brain is 25 Gy in 10 daily fractions. A shorter course (eg, 20 Gy in 5 fractions) may be appropriate in selected patients with extensive-stage disease. In a large randomized trial (PCI 99-01), patients receiving a dose of 36 Gy had higher mortality and higher chronic neurotoxicity compared to patients treated with 25 Gy.<sup>26,27</sup>
- Neurocognitive Function: Increasing age and higher doses are the most predictive factors for development of chronic neurotoxicity. In trial RTOG 0212, 83% of patients older than 60 years of age experienced chronic neurotoxicity 12 months after PCI versus 56% of patients younger than 60 years of age ( $P = .009$ ).<sup>27</sup> Concurrent systemic therapy and high total RT dose (>30 Gy) should be avoided in patients receiving PCI.
- Administer PCI after resolution of acute toxicities of initial therapy. PCI is not recommended in patients with poor performance status or impaired neurocognitive functioning.

**Brain Metastases:**

- Brain metastases should be treated with whole brain radiation therapy (WBRT) rather than stereotactic radiotherapy/radiosurgery (SRT/SRS) alone, because these patients tend to develop multiple CNS metastases. In patients who develop brain metastases after PCI, repeat WBRT may be considered in carefully selected patients.<sup>28,29</sup> SRS may also be considered, especially if there has been a long-time interval from initial diagnosis to occurrence of brain metastases and there is no uncontrolled extracranial disease.<sup>30,31</sup>
- Recommended dose for WBRT is 30 Gy in 10 daily fractions.

[General Principles, Limited Stage on SCL-D 1 of 3](#)  
[References on SCL-D 3 of 3](#)

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**PRINCIPLES OF RADIATION THERAPY****References**


- <sup>1</sup>Takada M, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. *J Clin Oncol* 2002;20:3054-3060.
- <sup>2</sup>Fried DB, Morris DE, Poole C, et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. *J Clin Oncol* 2004;22:4837-4845.
- <sup>3</sup>De Ruyscher D, Pijls-Johannesma M, Bentzen SM, et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. *J Clin Oncol* 2006;24:1057-1063.
- <sup>4</sup>Videtic GMM, Belderbos JSA, Kong F-MS, et al. Report from the International Atomic Energy Agency (IAEA) consultants' meeting on elective nodal irradiation in lung cancer: small-cell lung cancer (SCLC). *Int J Radiat Oncol Biol Phys* 2008;72:327-334.
- <sup>5</sup>De Ruyscher D, Bremer R-H, Koppe F, et al. Omission of elective node irradiation on basis of CT-scans in patients with limited disease small cell lung cancer: a phase II trial. *Radiother Oncol* 2006;80:307-312.
- <sup>6</sup>van Loon J, De Ruyscher D, Wanders R, et al. Selective nodal irradiation on basis of (18)FDG-PET scans in limited-disease small-cell lung cancer: a prospective study. *Int J Radiat Oncol Biol Phys* 2010;77:329-336.
- <sup>7</sup>Hu X, Bao Y, Zhang L, et al. Omitting elective nodal irradiation and irradiating postinduction versus preinduction chemotherapy tumor extent for limited-stage small cell lung cancer: interim analysis of a prospective randomized noninferiority trial. *Cancer* 2012;118:278-287.
- <sup>8</sup>Shirvani SM, Komaki R, Heymach JV, et al. Positron emission tomography/computed tomography-guided intensity-modulated radiotherapy for limited-stage small-cell lung cancer. *Int J Radiat Oncol Biol Phys* 2012;82:e91-97.
- <sup>9</sup>Xia B, Chen G-Y, Cai X-W, et al. Is involved-field radiotherapy based on CT safe for patients with limited-stage small-cell lung cancer? *Radiother Oncol* 2012;102:258-262.
- <sup>10</sup>Colaco R, Sheikh H, Lorigan P, et al. Omitting elective nodal irradiation during thoracic irradiation in limited-stage small cell lung cancer - Evidence from a phase II trial. *Lung Cancer* 2012;76:72-77.
- <sup>11</sup>Liengswangwong V, Bonner JA, Shaw EG, et al. Limited-stage small-cell lung cancer: patterns of intrathoracic recurrence and the implications for thoracic radiotherapy. *J Clin Oncol* 1994;12:496-502.
- <sup>12</sup>Turrisi AT, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. *N Engl J Med* 1999;340:265-271.
- <sup>13</sup>Schild SE, Bonner JA, Shanahan TG, et al. Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. *Int J Radiat Oncol Biol Phys* 2004;59:943-951.
- <sup>14</sup>Choi NC, Herndon JE, Rosenman J, et al. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. *J Clin Oncol* 1998;16:3528-3536.
- <sup>15</sup>Miller KL, Marks LB, Sibley GS, et al. Routine use of approximately 60 Gy once-daily thoracic irradiation for patients with limited-stage small-cell lung cancer. *Int J Radiat Oncol Biol Phys* 2003;56:355-359.
- <sup>16</sup>Roof KS, Fidas P, Lynch TJ, et al. Radiation dose escalation in limited-stage small-cell lung cancer. *Int J Radiat Oncol Biol Phys* 2003;57:701-708.
- <sup>17</sup>Bogart JA, Herndon JE, Lyss AP, et al. 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808. *Int J Radiat Oncol Biol Phys* 2004;59:460-468.
- <sup>18</sup>Komaki R, Paulus R, Ettinger DS, et al. Phase II study of accelerated high-dose radiotherapy with concurrent chemotherapy for patients with limited small-cell lung cancer: Radiation Therapy Oncology Group protocol 0239. *Int J Radiat Oncol Biol Phys* 2012;83:e531-6.
- <sup>19</sup>Jeremic B, Shibamoto Y, Nikolic N, et al. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: A randomized study. *J Clin Oncol* 1999;17:2092-2099.
- <sup>20</sup>Yee D, Butts C, Reiman A, et al. Clinical trial of post-chemotherapy consolidation thoracic radiotherapy for extensive-stage small cell lung cancer. *Radiother Oncol* 2012;102:234-238.
- <sup>21</sup>Slotman BJ, van Tinteren H, Praag JO, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. *Lancet*. 2015 Jan 3;385:36-42.
- <sup>22</sup>Arriagada R, Le Chevalier T, Rivière A, et al. Patterns of failure after prophylactic cranial irradiation in small-cell lung cancer: analysis of 505 randomized patients. *Annals of oncology* 2002;13:748-754.
- <sup>23</sup>Aupérin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. *N Engl J Med* 1999;341:476-484.
- <sup>24</sup>Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. *N Engl J Med* 2007;357:664-672.
- <sup>25</sup>Seto T, Takahashi T, Yamanaka T, et al. Prophylactic cranial irradiation (PCI) has a detrimental effect on the overall survival (OS) of patients (pts) with extensive disease small cell lung cancer (ED-SCLC): Results of a Japanese randomized phase III trial. *J Clin Oncol* 2014;32:(Suppl 5): Abstract 7503
- <sup>26</sup>Le Péchoux C, Dunant A, Senan S, et al. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. *The Lancet Oncology* 2009;10:467-474.
- <sup>27</sup>Wolfson AH, Bae K, Komaki R, et al. Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: Impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. *Int J Radiat Oncol Biol Phys* 2011;81:77-84.
- <sup>28</sup>Sadikov E, Bezzak A, Yi Q-L, et al. Value of whole brain re-irradiation for brain metastases--single centre experience. *Clinical oncology (Royal College of Radiologists (Great Britain))* 2007;19:532-538.
- <sup>29</sup>Son CH, Jimenez R, Niemierko A, et al. Outcomes after whole brain reirradiation in patients with brain metastases. *Int J Radiat Oncol Biol Phys* 2012;82:e167-172.
- <sup>30</sup>Harris S, Chan MD, Lovato JF, et al. Gamma knife stereotactic radiosurgery as salvage therapy after failure of whole-brain radiotherapy in patients with small-cell lung cancer. *Int J Radiat Oncol Biol Phys* 2012;83:e53-59.
- <sup>31</sup>Wegner RE, Olson AC, Kondziolka D, et al. Stereotactic radiosurgery for patients with brain metastases from small cell lung cancer. *Int J Radiat Oncol Biol Phys* 2011;81:e21-27.

**Note: All recommendations are category 2A unless otherwise indicated.****Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**



# NCCN Guidelines Version 2.2017

## Lung Neuroendocrine Tumors



<sup>a</sup>Management of endocrine symptoms as indicated (See the Carcinoid Tumors section in the [NCCN Guidelines for Neuroendocrine Tumors](#)).

<sup>b</sup>Mediastinal staging procedures include mediastinoscopy, mediastinotomy, endobronchial or esophageal ultrasound-guided biopsy, and video-assisted thoracoscopy. If endoscopic lymph node biopsy is positive, additional mediastinal staging is not required.

<sup>c</sup>PET scan is undergoing evaluation in clinical trials and should only be considered as a supplement and not a replacement to other studies.

<sup>d</sup>Stage-specific management of LCNEC follows the NSCLC algorithm. However, available data suggest that chemotherapy regimens commonly used for SCLC (see SCL-C) may represent the most reasonable option when systemic therapy is indicated. Niho S, Kenmotsu H, Sekine I, et al. Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study. *J Thorac Oncol* 2013;8:980-984; Rossi G, Cavazza A, Marchioni A, et al. Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFR $\alpha$ , PDGFR $\beta$ , and Met in large-cell neuroendocrine carcinoma of the lung. *J Clin Oncol* 2005;23:8774-8785; Le Treut J, Sault MC, Lena H, et al. Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study. *Ann Oncol* 2013;24:1548-1552.


**Note:** All recommendations are category 2A unless otherwise indicated.  
**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 2.2017

## Lung Neuroendocrine Tumors

### Low-Grade Lung Neuroendocrine Carcinoma (Typical Carcinoid)



<sup>e</sup>See [Staging on page ST-1](#).

<sup>f</sup>Wedge resection for peripheral low-grade neuroendocrine carcinoma (category 2B).

<sup>g</sup>See [Principles of Chemotherapy \(LNT-A\)](#).

<sup>h</sup>See [Principles of Radiation Therapy \(SCL-D\)](#).


**Note: All recommendations are category 2A unless otherwise indicated.**  
**Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**



# NCCN Guidelines Version 2.2017

## Lung Neuroendocrine Tumors

### Intermediate-Grade Lung Neuroendocrine Carcinoma (Atypical Carcinoid)



<sup>e</sup>See Staging on page ST-1.

<sup>g</sup>See Principles of Chemotherapy (LNT-A).

<sup>h</sup>See Principles of Radiation Therapy (SCL-D).

**Note:** All recommendations are category 2A unless otherwise indicated.  
**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**PRINCIPLES OF SYSTEMIC THERAPY****Low-Grade NET (Typical Carcinoid)\***

- Capecitabine + temozolomide<sup>1</sup>
- Everolimus<sup>2</sup>
- Cisplatin/etoposide<sup>3,4</sup>
- Temozolomide<sup>5</sup>
- Sunitinib<sup>6</sup>
- Consider octreotide or lanreotide, if octreotide scan positive or symptoms of carcinoid syndrome<sup>7,8</sup>

**Intermediate-Grade NET (Atypical Carcinoid)**

- Cisplatin/etoposide<sup>3,4</sup> (preferred)
- Capecitabine + temozolomide<sup>1</sup>
- Temozolomide<sup>5</sup>
- Sunitinib<sup>6</sup>
- Everolimus<sup>2</sup>
- Consider octreotide or lanreotide, if octreotide scan positive or symptoms of carcinoid syndrome<sup>7,8</sup>

\*There is no substantial evidence for a preferred regimen.

<sup>1</sup>Fine RL, Gulati AP, Krantz BA, et al. Capecitabine and temozolomide (CAPTEM) for metastatic well differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience. *Cancer Chemother Pharmacol* 2013;71:663-670.

<sup>2</sup>Fazio N, Granberg D, Grossman A, et al. Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study. *Chest* 2013;143:955-962.

<sup>3</sup>Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. *Cancer* 1991;68:227-232.

<sup>4</sup>Chong CR, Wirth LJ, Nishino M, et al. Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors. *Lung Cancer* 2014;86:241-246.

<sup>5</sup>Ekebal S, Sundin A, Janson ET, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. *Clin Cancer Res* 2007;13:2986-2991.

<sup>6</sup>Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. *J Clin Oncol* 2008;26:3403-3410;

<sup>7</sup>Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. *J Clin Oncol* 2009;27:4656-63.

<sup>8</sup>Caplin ME, Pavel M, Cwikla JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. *N Engl J Med* 2014;371:224-33.

**Note: All recommendations are category 2A unless otherwise indicated.**

**Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**



# NCCN Guidelines Version 2.2017 Staging Small Cell Lung Cancer/Lung Neuroendocrine Tumors

**Table 1 - Definition of small cell lung cancer consists of two stages:**

- (1) Limited-stage: AJCC (7th edition) Stage I-III (T any, N any, M0) that can be safely treated with definitive radiation doses. Excludes T3-4 due to multiple lung nodules that are too extensive or have tumor/nodal volume that is too large to be encompassed in a tolerable radiation plan.
- (2) Extensive-stage: AJCC (7th edition) Stage IV (T any, N any, M 1a/b), or T3-4 due to multiple lung nodules that are too extensive or have tumor/nodal volume that is too large to be encompassed in a tolerable radiation plan.

**Table 2 - Definitions of TNM<sup>1</sup>****T Primary Tumor**

- TX Primary tumor cannot be assessed, or tumor proven by the presence of malignant cells in sputum or bronchial washings but not visualized by imaging or bronchoscopy
- T0 No evidence of primary tumor
- Tis Carcinoma in situ
- T1 Tumor 3 cm or less in greatest dimension, surrounded by lung or visceral pleura, without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus)\*  
T1a Tumor 2 cm or less in greatest dimension  
T1b Tumor more than 2 cm but 3 cm or less in greatest dimension
- T2 Tumor with any of the following features of size or extent:
  - More than 3 cm but 7 cm or less
  - Involves main bronchus, 2 cm or more distal to the carina
  - Invades the visceral pleura (PL1 or PL2)
  - Associated with atelectasis or obstructive pneumonitis that extends to the hilar region but does not involve the entire lung
T2a Tumor more than 3 cm but 5 cm or less in greatest dimension  
T2b Tumor more than 5 cm but 7 cm or less in greatest dimension
- T3 Tumor more than 7 cm or one that directly invades any of the following: parietal pleural (PL3) chest wall (including superior sulcus tumors), diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium; or tumor in the main bronchus (less than 2 cm distal to the carina\* but without involvement of the carina); or associated atelectasis or obstructive pneumonitis of the entire lung or separate tumor nodule(s) in the same lobe
- T4 Tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, separate tumor nodule(s) in a different ipsilateral lobe

**N Regional Lymph Nodes**

- NX Regional lymph nodes cannot be assessed
- N0 No regional lymph node metastasis
- N1 Metastasis to ipsilateral peribronchial and/or ipsilateral hilar lymph nodes, and intrapulmonary nodes including involvement by direct extension
- N2 Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s)
- N3 Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s)

**M Distant Metastasis**

- M0 No distant metastasis
- M1 Distant metastasis  
M1a Separate tumor nodule(s) in a contralateral lobe tumor with pleural nodules or malignant pleural (or pericardial) effusion\*\*  
M1b Distant metastasis

\*The uncommon superficial spreading tumor of any size with its invasive component limited to the bronchial wall, which may extend proximally to the main bronchus, is also classified as T1a.

\*\*Most pleural (and pericardial) effusions with lung cancer are due to tumor. In a few patients, however, multiple cytopathologic examinations of pleura (pericardial) fluid are negative for tumor, and the fluid is nonbloody and is not an exudate. Where these elements and clinical judgment dictate that the effusion is not related to the tumor, the effusion should be excluded as a staging element and the patient should be classified as M0.

<sup>1</sup>Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original and primary source for this information is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer Science+Business Media, LLC (SBM). (For complete information and data supporting the staging tables, visit [www.springer.com](http://www.springer.com).) Any citation or quotation of this material must be credited to the AJCC as its primary source. The inclusion of this information herein does not authorize any reuse or further distribution without the expressed, written permission of Springer SBM, on behalf of the AJCC.

**Table 3 - Anatomic Stage/Prognostic Groups**

Occult carcinoma	TX	N0	M0
Stage 0	Tis	N0	M0
Stage IA	T1	N0	M0
Stage IB	T2a	N0	M0
Stage IIA	T2b	N0	M0
	T1	N1	M0
	T2a	N1	M0
Stage IIB	T2b	N1	M0
	T3	N0	M0
Stage IIIA	T1-2	N2	M0
	T3	N1-2	M0
	T4	N0-1	M0
Stage IIIB	T1-2	N3	M0
	T3	N3	M0
	T4	N2-3	M0
Stage IV	Any T	Any N	M1a
	Any T	Any N	M1b

Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original and primary source for this information is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer Science+Business Media, LLC (SBM). (For complete information and data supporting the staging tables, visit [www.springer.com](http://www.springer.com).) Any citation or quotation of this material must be credited to the AJCC as its primary source. The inclusion of this information herein does not authorize any reuse or further distribution without the expressed, written permission of Springer SBM, on behalf of the AJCC.



# NCCN Guidelines Version 2.2017

## Small Cell Lung Cancer

### Discussion

#### NCCN Categories of Evidence and Consensus

**Category 1:** Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

**Category 2A:** Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

**Category 2B:** Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.

**Category 3:** Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

**All recommendations are category 2A unless otherwise noted.**

### Table of Contents

Overview.....	MS-2
Literature Search Criteria and Guidelines Update Methodology....	MS-2
Small Cell Lung Cancer .....	MS-3
Diagnosis .....	MS-3
Screening.....	MS-3
Manifestations .....	MS-3
Pathology .....	MS-4
Staging.....	MS-4

Prognostic Factors .....	MS-6
Treatment.....	MS-6
Systemic Therapy.....	MS-6
Elderly Patients .....	MS-9
Second-Line and Beyond (Subsequent) Systemic Therapy.....	MS-10
Radiotherapy .....	MS-11
Thoracic Radiotherapy.....	MS-11
Prophylactic Cranial Irradiation .....	MS-13
Palliative Radiotherapy .....	MS-14
Surgical Resection of Stage I SCLC .....	MS-14
NCCN Guidelines .....	MS-15
Surveillance .....	MS-15
Lung Neuroendocrine Tumors .....	MS-16
Diagnosis and Staging .....	MS-16
Treatment.....	MS-16
References .....	MS-18

### Overview

Neuroendocrine tumors account for approximately 20% of lung cancers; most (approximately 14%) are small cell lung cancer (SCLC).<sup>1,2</sup> In 2016, an estimated 31,000 new cases of SCLC will occur in the United States.<sup>3</sup> Nearly all cases of SCLC are attributable to cigarette smoking.<sup>4</sup> Although the incidence of SCLC has been decreasing, the incidence in women is increasing and the male-to-female incidence ratio is now 1:1.<sup>2</sup> Management of SCLC and other lung neuroendocrine tumors (LNTs) is described in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for SCLC and for LNTs, which include the algorithms and this supporting Discussion text (see also *Lung Neuroendocrine Tumors* in this Discussion). The *Summary of the Guidelines Updates* section in the algorithm describes the most recent revisions, which have been incorporated into this revised Discussion (see the NCCN Guidelines® for SCLC). For the 2017 update for SCLC, nivolumab and ipilimumab were added as new options for second-line and beyond (ie, subsequent) systemic therapy;<sup>5</sup> new imaging guidelines for response assessment after systemic therapy were also added in addition to other changes as outlined in the summary updates. The NCCN Guidelines for SCLC were originally published 20 years ago and have been subsequently updated at least once every year (see [NCCN.org](#)).<sup>6</sup>

SCLC is characterized by a rapid doubling time, high growth fraction, and early development of widespread metastases. Most patients with SCLC present with hematogenous metastases; approximately one third present with limited disease confined to the chest. SCLC is highly sensitive to initial chemotherapy and radiotherapy; however, most patients eventually die of recurrent disease.<sup>7</sup> In patients with limited-stage SCLC, the goal of treatment is cure using chemotherapy plus thoracic radiotherapy.<sup>8,9</sup> In patients with extensive-stage disease,

chemotherapy alone can palliate symptoms and prolong survival in most patients; however, long-term survival is rare.<sup>10</sup> Note that the definitions for limited-stage and extensive-stage SCLC incorporate TNM staging (see the NCCN Guidelines for SCLC and *Staging* in this Discussion). Surgery is only appropriate for a few patients (2%–5%) with surgically resectable stage I SCLC.<sup>11</sup> Clinical trials generally represent state-of-the-art treatment for patients with SCLC. Despite recent advances, the standard therapy for SCLC as outlined by these NCCN Guidelines still needs to be improved. Thus, participation in clinical trials should be strongly encouraged.

Smoking cessation should be strongly promoted in patients with SCLC and other high-grade neuroendocrine carcinomas (see the NCCN Guidelines for Smoking Cessation, available at [NCCN.org](#)).<sup>12</sup> Former smokers should be strongly encouraged to remain abstinent. Patients with SCLC who continue to smoke have increased toxicity during treatment and shorter survival.<sup>13</sup> Programs using behavioral counseling combined with FDA-approved medications that promote smoking cessation can be very useful.

### Literature Search Criteria and Guidelines Update Methodology

Before the update of this version of the NCCN Guidelines for SCLC, an electronic search of the PubMed database was performed to obtain key literature in SCLC—published between April 1, 2015 and May 1, 2016—using the following search term: *small cell lung cancer*. The PubMed database was chosen, because it is the most widely used resource for medical literature and indexes only peer-reviewed biomedical literature. The search results were narrowed by selecting studies in humans published in English. Results were confined to the following article types: Clinical Trial, Phase 1; Clinical Trial, Phase 2; Clinical Trial,

Phase 3; Clinical Trial, Phase 4; Guideline; Randomized Controlled Trial; Meta-Analysis; Systematic Reviews; and Validation Studies.

The PubMed search resulted in 253 citations and their potential relevance was examined. The data from key PubMed articles as well as articles from additional sources deemed as relevant to these NCCN Guidelines and discussed by the panel have been included in this version of the Discussion section (eg, e-publications ahead of print, meeting abstracts). Recommendations for which high-level evidence is lacking are based on the panel's review of lower-level evidence and expert opinion. The complete details of the development and update of the NCCN Guidelines are available on the NCCN [webpage](#).

## Small Cell Lung Cancer

### Diagnosis

#### Screening

Ideally, a screening test should detect disease at an early stage when it is still curable. Currently, no effective screening test is available to detect early-stage SCLC; the disease is typically diagnosed when patients present with symptoms indicative of advanced-stage disease.<sup>14</sup>

The National Lung Screening Trial (NLST) reported that screening with annual, low-dose, spiral CT scans decreased lung cancer–specific mortality in asymptomatic high-risk individuals (see the NCCN Guidelines for Lung Cancer Screening, available at [NCCN.org](#)).<sup>15</sup>

Although low-dose CT screening can detect early-stage non-small cell lung cancer (NSCLC), it does not seem to be useful for detecting early-stage SCLC.<sup>14-16</sup> Low-dose CT screening is probably not useful because of the aggressiveness of SCLC, which results in the development of symptomatic disease between annual scans, thereby limiting the potential effect on mortality.<sup>14</sup>

#### Manifestations

SCLC typically presents as a large hilar mass and bulky mediastinal lymphadenopathy that cause cough and dyspnea.<sup>17</sup> Frequently, patients present with symptoms of widespread metastatic disease, such as weight loss, debility, bone pain, and neurologic compromise. It is uncommon for patients to present with a solitary peripheral nodule without central adenopathy. In this situation, fine-needle aspiration (FNA) may not adequately differentiate small cell carcinoma (which is a high-grade neuroendocrine carcinoma) from low-grade (typical carcinoid), intermediate-grade (atypical carcinoid), or large-cell neuroendocrine carcinoma (LCNEC) (which is also a high-grade neuroendocrine carcinoma) (see the NCCN Guidelines for Lung Neuroendocrine Tumors and *Lung Neuroendocrine Tumors* in this Discussion).<sup>18,19</sup>

Many neurologic and endocrine paraneoplastic syndromes are associated with SCLC.<sup>20-22</sup> Neurologic syndromes include Lambert-Eaton myasthenic syndrome, encephalomyelitis, and sensory neuropathy. Patients with the Lambert-Eaton syndrome present with proximal leg weakness that is caused by antibodies directed against the voltage-gated calcium channels.<sup>23,24</sup> Paraneoplastic encephalomyelitis and sensory neuropathy are caused by the production of an antibody (anti-*Hu*) that cross-reacts with both small cell carcinoma antigens and human neuronal RNA-binding proteins resulting in multiple neurologic deficits.<sup>25</sup>

SCLC cells sometimes produce polypeptide hormones, including vasopressin (antidiuretic hormone [ADH]) and adrenocorticotrophic hormone (ACTH), which cause hyponatremia of malignancy (ie, syndrome of inappropriate ADH secretion [SIADH]) and Cushing syndrome, respectively.<sup>26,27</sup> In patients with SCLC, SIADH occurs more frequently than Cushing syndrome. Cancer treatment and/or supportive

care may also cause hyponatremia (eg, cisplatin, opiates).<sup>28</sup> Treatment for SIADH includes fluid restriction (which is difficult for patients because of increased thirst), demeclocycline, or vasopressin receptor inhibitors (ie, conivaptan, tolvaptan) (see *Principles of Supportive Care* in the NCCN Guidelines for SCLC).<sup>28-30</sup> ADH levels and hyponatremia usually improve after successful treatment for SCLC.

### Pathology

SCLC is a malignant epithelial tumor consisting of small cells with scant cytoplasm, ill-defined cell borders, finely granular nuclear chromatin, and absent or inconspicuous nucleoli.<sup>18,31</sup> The cells are round, oval, or spindle-shaped; nuclear molding is prominent. The mitotic count is high. The classic and distinctive histology on hematoxylin and eosin (H&E) may be sufficient for identifying SCLC; it is a poorly differentiated tumor that is categorized as a high-grade neuroendocrine carcinoma.<sup>18</sup> Up to 30% of autopsies in patients with SCLC reveal areas of NSCLC differentiation; this finding is more commonly detected in specimens from previously treated patients and suggests that pulmonary carcinogenesis occurs in a pluripotent stem cell capable of differentiation along divergent pathways.

Although 95% of small cell carcinomas originate in the lung, they can also arise from extrapulmonary sites, including the nasopharynx, gastrointestinal tract, and genitourinary tract.<sup>32,33</sup> Both pulmonary and extrapulmonary small cell carcinomas have a similar clinical and biologic behavior, leading to a high potential for widespread metastases.

Nearly all SCLCs are immunoreactive for keratin, epithelial membrane antigen, and thyroid transcription factor-1 (TTF-1).<sup>18</sup> Most SCLCs also stain positively for markers of neuroendocrine differentiation, including chromogranin A, neuron-specific enolase, neural cell adhesion molecule

(NCAM; CD56), and synaptophysin.<sup>18</sup> However, these markers alone cannot be used to distinguish SCLC from NSCLC, because approximately 10% of NSCLCs will be immunoreactive for at least one of these neuroendocrine markers.<sup>34</sup>

### Staging

The NCCN Panel adopted a combined approach for staging SCLC using both the AJCC TNM staging system and the older Veterans Administration (VA) scheme for SCLC (see the following 2 paragraphs).<sup>7,35</sup> Historically, contralateral mediastinal and ipsilateral supraclavicular lymphadenopathy were generally classified as limited-stage disease, whereas the classification of contralateral hilar and supraclavicular lymphadenopathy is more controversial and treatment is individualized for the patients.<sup>7,35,36</sup> Approximately 66% of patients present with overt hematogenous metastases, which commonly involve the contralateral lung, liver, adrenal glands, brain, bones, and/or bone marrow. The AJCC is currently revising the TNM staging system for SCLC; new staging guidelines will be published in late 2016.<sup>37</sup> The SCLC panel will continue to use the combined VA/TNM system for staging SCLC after publication of the 8<sup>th</sup> edition of the AJCC Cancer Staging Manual.

In 2010, the lung cancer TNM staging system was revised by the International Association for the Study of Lung Cancer (IASLC) and adopted by the AJCC (7<sup>th</sup> edition, 2010) (see Tables 2 and 3 in the NCCN Guidelines for SCLC).<sup>38-41</sup> This TNM staging system is applicable to both NSCLC and SCLC based on studies that showed the prognostic significance of the various stage designations in both diseases.<sup>38,40</sup> In the combined approach for staging SCLC, *limited-stage* SCLC is defined as stage I to III (T any, N any, M0) that can be safely treated with definitive radiation therapy, excluding T3-4 due to multiple lung



# NCCN Guidelines Version 2.2017

## Small Cell Lung Cancer

nodules that are too extensive or have tumor/nodal volume that is too large to be encompassed in a tolerable radiation plan (see Table 1 in the NCCN Guidelines for SCLC). *Extensive-stage* SCLC is defined as stage IV (T any, N any, M1a/b) or T3–4 due to multiple lung nodules that are too extensive or have tumor/nodal volume that is too large to be encompassed in a tolerable radiation plan.

The VA Lung Study Group's 2-stage classification scheme is also used to define the extent of disease in patients with SCLC: 1) limited-stage disease is disease confined to the ipsilateral hemithorax, which can be safely encompassed within a radiation field; and 2) extensive-stage disease is disease beyond the ipsilateral hemithorax, including malignant pleural or pericardial effusion or hematogenous metastases.<sup>42</sup> Because most of the literature on SCLC classifies patients based on the VA's definitions of limited-stage or extensive-stage disease, these definitions are often used for clinical decision making. However, the TNM system is useful for selecting patients with T1-2, N0 disease who are eligible for surgery and for radiation treatment planning.<sup>35</sup> Clinical research studies should begin to use the TNM system, because it will allow for more precise assessments of prognosis and specific therapy in the future.

All patients with SCLC, even those with radiographically limited-stage disease (per the VA's definition), require systemic therapy either as primary or adjuvant therapy. Therefore, staging provides a therapeutic guideline for thoracic radiotherapy, which is indicated primarily for patients with limited-stage disease. Full staging includes a history and physical examination; CT scan (with intravenous contrast) of the chest, liver, and adrenal glands; and brain imaging using MRI (preferred) or CT scan (with intravenous contrast).<sup>36</sup> However, once a patient has been found to have extensive-stage disease, further staging is optional, except for brain imaging.<sup>7</sup> Unilateral bone marrow aspirates and

biopsies may be indicated in select patients with nucleated red blood cells on peripheral blood smear, neutropenia, or thrombocytopenia suggestive of bone marrow infiltration and with no other evidence of metastatic disease. Bone marrow involvement as the only site of extensive-stage disease occurs in fewer than 5% of patients. If limited-stage disease is suspected, a PET/CT scan can be performed to assess for distant metastases.<sup>7,35</sup> A bone scan can be performed if PET/CT is equivocal or not available.

PET scans can increase staging accuracy in patients with SCLC, because SCLC is a highly metabolic disease.<sup>43-45</sup> PET/CT is superior to PET alone.<sup>45</sup> Approximately 19% of patients who undergo PET are upstaged from limited- to extensive-stage disease, whereas only 8% are downstaged from extensive- to limited-stage disease.<sup>36</sup> For most metastatic sites, PET/CT is superior to standard imaging; however, PET/CT is inferior to MRI or CT for the detection of brain metastases (see the NCCN Guidelines for Central Nervous System Cancers, available at [NCCN.org](#)).<sup>46</sup> Changes in management based on PET staging were reported in approximately 27% of patients, mainly because of alterations in the planned radiation field as a result of improved detection of intrathoracic sites of disease.<sup>36,44,47</sup> Although PET/CT seems to improve staging accuracy in SCLC, pathologic confirmation is still required for PET/CT–detected lesions that result in upstaging.

Before surgical resection, pathologic mediastinal staging is required to confirm PET/CT scan results in patients who seem to have clinical stage T1–2, N0 disease.<sup>7</sup> However, mediastinal staging is not required if the patient is not a candidate for surgical resection or if non-surgical treatment is planned. Invasive mediastinal staging can be performed either by conventional mediastinoscopy or by minimally invasive techniques such as transesophageal endoscopic ultrasound–guided FNA (EUS-FNA), endobronchial ultrasound–guided transbronchial

needle aspiration (EBUS-TBNA), or video-assisted thoracoscopy (VATS).<sup>48,49</sup>

Thoracentesis with cytologic analysis is recommended if a pleural effusion is large enough to be safely accessed via ultrasound guidance. If thoracentesis does not show malignant cells, then thoracoscopy can be considered to document pleural involvement, which would indicate extensive-stage disease. The effusion should be excluded as a staging element if: 1) multiple cytopathologic examinations of the pleural fluid are negative for cancer; 2) the fluid is not bloody and not an exudate; and 3) clinical judgment suggests that the effusion is not directly related to the cancer. Pericardial effusions are classified using the same criteria.

Staging should not focus only on sites of symptomatic disease or on sites suggested by laboratory tests. Bone scans are positive in up to 30% of patients without bone pain or an abnormal alkaline phosphatase level. Bone imaging with radiographs or MRI may be appropriate if PET/CT is equivocal. Brain imaging (MRI preferred or CT scan) can identify central nervous system (CNS) metastases in 10% to 15% of patients at diagnosis, of which approximately 30% are asymptomatic. Early treatment of brain metastases results in less chronic neurologic morbidity, arguing for the usefulness of early diagnosis in asymptomatic patients. Because of the aggressive nature of SCLC, staging should not delay the onset of treatment for more than 1 week; otherwise, many patients may become more seriously ill in the interval, with a significant decline in their performance status (PS).

### Prognostic Factors

Poor PS (3–4), extensive-stage disease, weight loss, and markers associated with excessive bulk of disease (such as lactate dehydrogenase [LDH]) are the most important adverse prognostic

factors. Female gender, age younger than 70 years, normal LDH, and stage I disease are associated with a more favorable prognosis in patients with limited-stage disease. Younger age, good PS, normal creatinine level, normal LDH, and a single metastatic site are favorable prognostic factors in patients with extensive-stage disease.<sup>50,51</sup>

### Treatment

#### Systemic Therapy

For all patients with SCLC, chemotherapy is an essential component of appropriate treatment. Adjuvant chemotherapy is recommended for those who have undergone surgical resection. For patients with limited-stage SCLC in excess of T1-2, N0 and good PS (0–2), recommended treatment consists of chemotherapy with concurrent thoracic radiotherapy (category 1).<sup>9,52,53</sup> For patients with extensive-stage disease, chemotherapy alone is the recommended treatment, although radiotherapy may be used in select patients for palliation of symptoms (see *Initial Treatment* and *Principles of Systemic Therapy* in the NCCN Guidelines for SCLC). In patients with extensive-stage and brain metastases, chemotherapy can be given either before or after whole-brain radiotherapy depending on whether the patient has neurologic symptoms (see *Initial Treatment* in the NCCN Guidelines for SCLC).<sup>10,54</sup>

For the 2017 update, the NCCN Panel added new recommendations for response assessment during and after therapy in patients with limited-stage or extensive-stage SCLC. After adjuvant chemotherapy alone or chemotherapy with concurrent RT for patients with limited-stage disease, response assessment using CT with contrast of the chest, liver, and adrenal gland should occur only after completion of initial therapy; repeating scans during therapy is not recommended. For systemic therapy alone or sequential systemic therapy followed by RT in patients with limited-stage disease, response assessment using CT



with contrast of the chest, liver, and adrenal gland should occur after every 2 cycles of systemic therapy and again at completion of therapy. During systemic therapy for patients with extensive-stage disease, response assessment using CT with contrast of the chest, liver, and adrenal gland should occur after every 2 to 3 cycles of chemotherapy and again at completion of therapy. Scanning for brain metastases is also recommended in patients with extensive-stage disease who have asymptomatic brain metastases and are receiving systemic therapy before whole-brain RT; brain MRI (preferred) or brain CT with contrast should occur after every 2 cycles of chemotherapy and again at completion of therapy.

Single-agent and combination chemotherapy regimens have been shown to be active in SCLC. Etoposide and cisplatin (EP) is the most commonly used initial combination chemotherapy regimen (see *Principles of Systemic Therapy* in the NCCN Guidelines for SCLC).<sup>55</sup> This combination replaced alkylator/anthracycline-based regimens based on its superiority in both efficacy and toxicity in the limited-stage setting.<sup>56</sup> EP plus concurrent thoracic radiotherapy is the recommended therapy for patients with limited-stage disease in excess of T1-2, N0 (category 1).<sup>52,53,57,58</sup>

In combination with thoracic radiotherapy, EP causes an increased risk of esophagitis, pulmonary toxicity, and hematologic toxicity.<sup>59</sup> The use of myeloid growth factors is not recommended (category 1 for not using GM-CSF) in patients undergoing concurrent chemoradiation.<sup>60</sup> In clinical practice, carboplatin is frequently substituted for cisplatin to reduce the risk of emesis, neuropathy, and nephropathy.<sup>61</sup> However, the use of carboplatin carries a greater risk of myelosuppression.<sup>62</sup> Small randomized trials have suggested similar efficacy of cisplatin and carboplatin in patients with SCLC as did a retrospective analysis in patients with extensive-stage disease.<sup>61,63,64</sup> A meta-analysis of

individual patient data from 4 randomized studies compared cisplatin-based versus carboplatin-based regimens in patients with SCLC.<sup>65</sup> Of 663 patients included in this meta-analysis, 32% had limited-stage disease and 68% had extensive-stage disease. No significant difference was observed in response rate (67% vs. 66%), progression-free survival (5.5 vs. 5.3 months), or overall survival (9.6 vs. 9.4 months) in patients receiving cisplatin- versus carboplatin-containing regimens, suggesting equivalent efficacy in patients with SCLC.

Many other combinations have been evaluated in patients with extensive-stage disease, with little consistent evidence of benefit when compared with EP. The combination of irinotecan and a platinum agent initially appeared to be better than EP. A small phase 3 trial performed in Japan reported that patients with extensive-stage SCLC who were treated with irinotecan plus cisplatin experienced a median survival of 12.8 months compared with 9.4 months for patients treated with EP ( $P=.002$ ).<sup>66</sup> In addition, the 2-year survival was 19.5% in the irinotecan plus cisplatin group versus 5.2% in the EP group.<sup>66</sup> However, 2 subsequent large phase 3 trials performed in the United States comparing irinotecan plus cisplatin with EP failed to show a significant difference in response rate or overall survival between the regimens.<sup>67,68</sup>

A phase 3 randomized trial ( $n = 220$ ) found that median overall survival was slightly improved with irinotecan and carboplatin compared with carboplatin and oral etoposide (8.5 vs. 7.1 months,  $P = .04$ ).<sup>69</sup> Based on these findings, the carboplatin and irinotecan regimen is an option in the NCCN Guidelines for patients with extensive-stage disease. A meta-analysis suggests an improvement in PFS and overall survival with irinotecan plus platinum regimens compared with etoposide plus platinum regimens.<sup>70</sup> However, this meta-analysis was not performed using data from individual patients. In addition, the relatively small

absolute survival benefit needs to be balanced against the toxicity profile of irinotecan-based regimens. Therefore, the NCCN Panel continues to consider etoposide plus platinum as the standard regimen for patients with either limited-stage or extensive-stage SCLC.

In patients with limited-stage disease, response rates of 70% to 90% are expected after treatment with EP plus thoracic radiotherapy, whereas in extensive-stage disease, response rates of 60% to 70% can be achieved with combination chemotherapy alone. Unfortunately, median survival rates are only 14 to 20 months and 9 to 11 months for patients with limited- and extensive-stage disease, respectively. After appropriate treatment, the 2-year survival rate is approximately 40% in patients with limited-stage disease, but less than 5% in those with extensive-stage disease.<sup>71</sup> Thoracic radiotherapy improves local control rates by 25% in patients with limited-stage disease and is associated with improved survival.<sup>52,53</sup> Data suggest that chemoradiotherapy may be indicated for patients with limited-stage disease who have cytologically negative or indeterminate pleural effusions, but not for those with pericardial effusions.<sup>72,73</sup>

Many strategies have been evaluated in an effort to improve on the standard treatment for extensive-stage SCLC, including the addition of a third agent to standard 2-drug regimens. In 2 trials, the addition of ifosfamide (or cyclophosphamide plus an anthracycline) to EP showed a modest survival advantage for patients with extensive-stage disease.<sup>74,75</sup> However, these findings have not been uniformly observed, and the addition of an alkylating agent, with or without an anthracycline, significantly increases hematologic toxicity when compared to EP alone.<sup>76</sup> Similarly, the addition of paclitaxel to either cisplatin or carboplatin plus etoposide yielded promising results in phase 2 trials but did not improve survival and was associated with unacceptable toxicity in a subsequent phase 3 study.<sup>77</sup> The use of maintenance or

consolidation chemotherapy beyond 4 to 6 cycles of standard treatment produces a minor prolongation of duration of response without improving survival and carries a greater risk of cumulative toxicity.<sup>78</sup> A meta-analysis reported that maintenance chemotherapy did not prolong overall survival.<sup>79</sup>

The inability to destroy residual cells, despite the initial chemosensitivity of SCLC, suggests the existence of cancer stem cells that are relatively resistant to cytotoxic therapy. To overcome drug resistance, alternating or sequential combination therapies have been designed to expose the tumor to as many active cytotoxic agents as possible during initial treatment.<sup>80</sup> However, randomized trials have failed to show improved PFS or overall survival with this approach.<sup>81,82</sup>

Multidrug cyclic weekly therapy was designed to increase dose intensity. Early phase 2 results of this approach were promising, although favorable patient selection was of some concern.<sup>83,84</sup> Nevertheless, no survival benefits were documented in randomized trials, and excessive treatment-related mortality was noted with multidrug cyclic weekly regimens.<sup>85-88</sup> The role of higher-dose therapy for patients with SCLC remains controversial. Higher complete and partial response rates, and modestly longer median survival times, have been observed in patients receiving high doses when compared with those given conventional doses of the same agents.<sup>89</sup> In general, however, randomized trials comparing conventional doses to an incrementally increased dose intensity up to 2 times the conventional dose have not consistently shown an increase in response rate or survival.<sup>90-93</sup> In addition, a meta-analysis of trials that compared standard versus dose-intense variations of the cyclophosphamide, doxorubicin, and vincristine (CAV) and EP regimens found that increased relative dose intensity resulted in only a small, clinically

insignificant enhancement of median survival in patients with extensive-stage disease.<sup>94</sup>

Currently available cytokines (eg, granulocyte-macrophage colony-stimulating factor [GM-CSF], granulocyte colony-stimulating factor) can ameliorate chemotherapy-induced myelosuppression and reduce the incidence of febrile neutropenia, but cumulative thrombocytopenia remains dose limiting. Although trials involving patients with SCLC were instrumental in obtaining FDA approval for the clinical use of cytokines,<sup>95</sup> maintenance of dose intensity with growth factors does not prolong disease-free or overall survival.<sup>96,97</sup> Thus, the routine use of growth factors at the initiation of systemic therapy is not recommended.

The benefits of antiangiogenic therapy are being evaluated in SCLC. In patients with limited-stage SCLC, a phase 2 study of irinotecan, carboplatin, and bevacizumab with concurrent radiotherapy followed by maintenance bevacizumab was terminated early because of an unacceptable incidence of tracheoesophageal fistulae. In extensive-stage SCLC, phase 2 trials of platinum-based chemotherapy plus bevacizumab have yielded promising response and survival data.<sup>98-101</sup> However, at least one randomized trial has demonstrated no survival benefit for the addition of bevacizumab to standard chemotherapy.<sup>102</sup> Other randomized phase 3 trials are ongoing in patients with extensive-stage SCLC.<sup>103</sup> Currently, the NCCN Panel does not recommend use of bevacizumab in patients with SCLC.

Although immune checkpoint inhibitors have demonstrated activity in a variety of cancers, including SCLC, a recent phase 3 randomized trial reported that the addition of ipilimumab to etoposide with either cisplatin or carboplatin did not improve either overall survival or PFS in patients with extensive-stage SCLC.<sup>104</sup> Overall, attempts to improve long-term

survival rates in patients with SCLC through the addition of more agents or the use of dose-intense chemotherapy regimens, maintenance therapy, or alternating non-cross-resistant chemotherapy regimens have failed to yield significant advantages when compared to standard approaches.

### *Elderly Patients*

The incidence of lung cancer increases with age. Although the median age at diagnosis is 70 years, elderly patients are under-represented in clinical trials.<sup>105</sup> Although advanced chronologic age adversely affects tolerance to treatment, the functional status of an individual patient is much more useful than age in guiding clinical decision making (see the NCCN Guidelines for Senior Adult Oncology, available at [NCCN.org](#)). Older patients who are functional in terms of the ability to perform activities of daily living should be treated with standard combination chemotherapy (and radiotherapy, if indicated).<sup>106,107</sup> However, myelosuppression, fatigue, and lower organ reserves are encountered more frequently in elderly patients; therefore, they must be watched carefully during treatment to avoid excessive risk. Greater attention to the needs and support systems of elderly patients is recommended to provide optimal care. Overall, elderly patients have a similar prognosis as stage-matched younger patients.

Randomized trials have indicated that less-intensive treatment (eg, single-agent etoposide) is inferior to combination chemotherapy (eg, platinum plus etoposide) in elderly patients with good PS (0–2).<sup>108,109</sup> A recent retrospective analysis in 8637 elderly patients with limited-stage disease reported that chemoradiation increased survival when compared with chemotherapy alone.<sup>106</sup> Several other strategies have been evaluated in elderly patients with SCLC.<sup>64,110-112</sup> The use of 4 cycles of carboplatin plus etoposide seems to yield favorable results, because the area-under-the-curve (AUC) dosing of carboplatin takes



into account the declining renal function of the aging patient.<sup>112</sup> However, targeting carboplatin to an AUC of 5, rather than 6, is more reasonable in this population.<sup>113</sup> The usefulness of short-course, full-intensity chemotherapy has also been explored in elderly or infirm patients, and the results with only 2 cycles of chemotherapy seem to be acceptable, although this approach has not been directly compared with standard therapy.<sup>114</sup>

#### *Second-Line and Beyond (Subsequent) Systemic Therapy*

Although SCLC is very responsive to initial treatment, most patients relapse with relatively resistant disease.<sup>115,116</sup> These patients have a median survival of only 4 to 5 months when treated with further systemic therapy. Subsequent systemic therapy provides significant palliation in many patients, although the likelihood of response is highly dependent on the time from initial therapy to relapse.<sup>117</sup> If this interval is less than 3 months (refractory or resistant disease), response to most agents or regimens is poor ( $\leq 10\%$ ). If more than 3 months have elapsed (sensitive disease), expected response rates are approximately 25%. If patients relapse more than 6 months after first-line treatment, then treatment with their original regimen is recommended.<sup>7,117,118</sup> Response assessment should occur after every 2 to 3 cycles of subsequent systemic therapy using CT with contrast of the chest/liver/adrenal gland. Dose reduction or growth factor support should be considered for patients with PS 2 who are receiving subsequent systemic therapy.

Based on phase 2 trials, recommended subsequent systemic therapy agents for patients who have relapsed 6 months or less after primary therapy include topotecan, irinotecan, paclitaxel, docetaxel, temozolomide, nivolumab with or without ipilimumab, vinorelbine, oral etoposide, gemcitabine, CAV, and bendamustine (category 2A for all agents except for bendamustine, which is a category 2B recommendation) (see *Principles of Systemic Therapy* in the NCCN

Guidelines for SCLC).<sup>119-122</sup> These agents are listed in order of preference in the NCCN Guidelines. Ifosfamide was deleted for the 2017 update, because panel members no longer use this agent.

For the 2017 update, the NCCN Panel added recommendations for nivolumab and nivolumab plus ipilimumab (both are category 2A) as options for subsequent therapy for patients who have relapsed 6 months or less after primary therapy. Nivolumab and ipilimumab are novel immunotherapeutic agents that stimulate the immune system and thus have different mechanisms of action when compared with standard cytotoxic chemotherapy.<sup>123</sup> These recommendations are based on a recent phase 1/2 trial in which patients received either nivolumab alone or various doses of nivolumab with ipilimumab for relapsed SCLC.<sup>5</sup> Response rates were 10% (10/98) for nivolumab 3 mg/kg, 23% (14/61) for nivolumab 1 mg/kg plus ipilimumab 3 mg/kg, and 19% (10/54) for nivolumab 3 mg/kg plus ipilimumab 1 mg/kg. The responses did not correlate with PD-L1 expression; studies indicate the SCLC has a lower rate of PD-L1 expression than NSCLC.<sup>5</sup> Diarrhea was the most common grade 3 or 4 treatment-related adverse event. The overall frequency of grade 3 or 4 adverse events was about 20%, and fewer than 10% of patients discontinued treatment because of treatment-related adverse events.

Preliminary data suggest that temozolomide may be useful for patients with SCLC, especially those with brain metastases and methylated O<sup>6</sup>-methylguanine-DNA methyltransferase (MGMT).<sup>120,124</sup> A recent phase 3 trial (JCOG0605) from Japan in patients with sensitive relapsed SCLC reported that the combination of cisplatin, etoposide, and irinotecan improved survival (median, 18.2 months; 95% CI, 15.7–20.6) when compared with topotecan (12.5 months, 10.8–14.9; hazard ratio [HR], 0.67; 90% CI, 0.51–0.88;  $P = .0079$ ). However, the toxicity of this

approach was significant, and it is not recommended as standard second-line therapy.<sup>125</sup>

A randomized phase 3 trial compared single-agent intravenous topotecan with the combination regimen CAV.<sup>126</sup> Both arms had similar response rates and survival, but intravenous topotecan caused less toxicity. In another phase 3 trial, oral topotecan improved overall survival when compared with best supportive care (26 vs. 14 weeks).<sup>127</sup> Single-agent topotecan is approved by the FDA as subsequent therapy for patients with SCLC who relapse after initial response to chemotherapy. Either oral or intravenous topotecan may be used, because efficacy and toxicity seem to be similar with either route.<sup>127,128</sup>

Many practicing oncologists have noted excessive toxicity with the standard regimen of 1.5 mg/m<sup>2</sup> of intravenous topotecan for 5 days, and studies suggest that an attenuated dose may be equally efficacious with lower toxicity.<sup>129</sup> Published studies have yielded conflicting data regarding the usefulness of weekly topotecan in patients with relapsed SCLC, and this approach remains under investigation.<sup>130,131</sup> Amrubicin is an active drug in patients with relapsed or refractory SCLC.<sup>132-135</sup> However, grade 3–4 toxicity, primarily neutropenia, is common.<sup>136,137</sup> A phase 3 trial reported that amrubicin did not improve overall survival as second-line treatment for SCLC when compared to topotecan, except in a subset of patients with refractory disease.<sup>138</sup>

The optimal duration of subsequent systemic therapy has not been fully explored, although its duration is usually short and the cumulative toxicity is frequently limiting even in patients who experience response. For these reasons, subsequent systemic therapy should be continued until 2 cycles beyond best response, progression of disease, or development of unacceptable toxicity. Additional subsequent systemic therapy (eg, third line) can be considered if patients are still PS 0-2.

### **Radiotherapy**

The *Principles of Radiation Therapy* in the algorithm describe the radiation doses, target volumes, and normal tissue dose volume constraints for mainly limited-stage SCLC, and include references to support the recommendations; prophylactic cranial irradiation (PCI) and treatment of brain metastases are also discussed (see the NCCN Guidelines for SCLC). The American College of Radiology (ACR) Appropriateness Criteria® are a useful resource.<sup>139</sup> The *Principles of Radiation Therapy* in the NSCLC algorithm may also be useful (eg, general principles of radiotherapy, palliative radiotherapy) (see the NCCN Guidelines for NSCLC, available at [NCCN.org](#)). This section describes the studies supporting the NCCN recommendations for SCLC. A few reports have suggested that stereotactic ablative radiotherapy (SBRT) might be useful for select patients with limited-stage SCLC; however, there are insufficient data to make a recommendation.<sup>140,141</sup>

### **Thoracic Radiotherapy**

The addition of thoracic radiotherapy has improved survival for patients with limited-stage disease. Meta-analyses that included more than 2000 patients show that thoracic radiation for limited-stage disease yields a 25% to 30% reduction in local failure, and a corresponding 5% to 7% improvement in 2-year survival when compared with chemotherapy alone.<sup>52,53</sup> However, achieving long-term local control using conventional chemoradiotherapy for patients with limited-stage SCLC remains a challenge.

### **Timing of Radiation with Chemotherapy**

The administration of thoracic radiotherapy requires the assessment of several factors, including the timing of chemotherapy and radiotherapy (concurrent vs. sequential), timing of radiotherapy (early vs. late), volume of the radiation port (original tumor volume vs. shrinking field as



the tumor responds), dose of radiation, and fractionation of radiotherapy. Early concurrent chemoradiotherapy is recommended for patients with limited-stage SCLC based on randomized trials. A randomized phase 3 trial by the Japanese Cooperative Oncology Group assessed sequential versus concurrent thoracic radiotherapy combined with EP for patients with limited-stage disease. They reported that patients treated with concurrent radiotherapy lived longer than those treated with sequential radiotherapy.<sup>59</sup>

Another randomized phase 3 trial (by the National Cancer Institute of Canada)—comparing radiotherapy beginning with either cycle 2 or cycle 6 of chemotherapy—showed that early radiotherapy was associated with improved local and systemic control and with longer survival.<sup>142</sup> Several systematic reviews and meta-analyses on the timing of thoracic radiotherapy in limited-stage SCLC have reported that early concurrent radiotherapy results in a small, but significant improvement in overall survival when compared with late concurrent or sequential radiotherapy.<sup>143,144</sup> Another meta-analysis in patients with limited-stage SCLC showed that survival was improved with more rapid completion of the chemo/RT regimen (start of any chemotherapy until the end of radiotherapy [SER]).<sup>145</sup> A recent meta-analysis of individual patient data from 12 trials (2,668 patients) reported that early concurrent chemo/RT increased 5-year overall survival (HR, 0.79; 95% CI, 0.69–0.91), although severe acute esophagitis was also increased, when compared with late concurrent therapy.<sup>146</sup>

### Radiation Fractionation

The ECOG/Radiation Therapy Oncology Group compared once-daily to twice-daily radiotherapy with EP.<sup>147</sup> In this trial, 412 patients with limited-stage SCLC were treated with concurrent chemoradiotherapy using a total dose of 45 Gy delivered either twice a day over 3 weeks or once a day over 5 weeks. The twice-daily schedule produced a survival

advantage, but a higher incidence of grade 3 to 4 esophagitis was seen when compared with the once-daily regimen. Median survivals were 23 versus 19 months ( $P = .04$ ), and 5-year survival rates were 26% versus 16% in the twice-daily and once-daily radiotherapy arms, respectively.<sup>147</sup> A significant criticism of this trial is that the doses of radiation in the 2 arms were not biologically equivalent. In light of this, ongoing trials are evaluating biologically equivalent doses of 45 Gy delivered twice daily versus 60 to 70 Gy delivered once daily.<sup>148</sup> Another concern regarding hyperfractionation is that twice-daily thoracic radiation is technically challenging for patients with bilateral mediastinal adenopathy.

Another randomized phase 3 trial showed no survival difference between once-daily thoracic radiotherapy to 50.4 Gy with concurrent EP and a split course of twice-daily thoracic radiotherapy to 48 Gy with concurrent EP.<sup>149</sup> However, split-course radiotherapy may be less efficacious because of interval tumor regrowth between courses. Overall, patients selected for combined modality treatment that incorporates twice-daily radiotherapy must have an excellent PS and good baseline pulmonary function.

### NCCN Guideline for Radiation in Limited-Stage SCLC

For limited-stage disease in excess of T1-2, N0, the NCCN Guidelines recommend that radiotherapy should be used concurrently with chemotherapy and that radiotherapy should start with the first or second cycle (category 1). The optimal dose and schedule of radiotherapy have not been established. However, 45 Gy in 3 weeks (twice-daily regimen) is superior to 45 Gy once daily in 5 weeks.<sup>147</sup> For twice-daily radiotherapy, the recommended schedule is 1.5 Gy twice daily to a total dose of 45 Gy in 3 weeks (category 1). For once-daily radiotherapy, the recommended schedule is 2.0 Gy once daily to a total dose of 60 to 70 Gy (see *Principles of Radiation Therapy* in the NCCN Guidelines for SCLC).<sup>150-152</sup> The minimum standard for thoracic irradiation is

CT-planned 3-D conformal radiotherapy. More advanced technologies may also be used when needed (eg, 4D-CT) (see *Principles of Radiation Therapy* in the NCCN Guidelines for SCLC). The radiation target volumes can be defined on the PET/CT scan obtained at the time of radiotherapy planning using definitions in reports 50 and 62 from the International Commission on Radiation Units & Measurement (ICRU).<sup>153,154</sup> However, the pre-chemotherapy PET/CT scan should be reviewed to include the originally involved lymph node regions in the treatment fields.<sup>152,155</sup>

The normal tissue constraints used for NSCLC are appropriate for SCLC when using similar radiotherapy doses (see the NCCN Guidelines for NSCLC, available at [NCCN.org](http://NCCN.org)). When using accelerated schedules (eg, 3–5 weeks), the spinal cord constraints from the CALCB 30610/RTOG 0538 protocol can be used as a guide (see *Principles of Radiation Therapy* in the NCCN Guidelines for SCLC).<sup>156-158</sup> Intensity-modulated radiation therapy (IMRT) may be considered in select patients (see *Principles of Radiation Therapy* in the NCCN Guidelines for SCLC and the NCCN Guidelines for NSCLC).<sup>159-163</sup>

### Thoracic Radiation in Extensive-Stage SCLC

Based on the results of a randomized trial by Jeremic et al,<sup>164</sup> the addition of sequential thoracic radiotherapy may be considered in select patients with low-bulk metastatic extensive-stage disease who have a complete or near complete response after initial chemotherapy. In this trial, patients experiencing a complete response at distant metastatic sites after 3 cycles of EP were randomized to receive either 1) further EP; or 2) accelerated hyperfractionated radiotherapy (ie, 54 Gy in 36 fractions over 18 treatment days) in combination with carboplatin plus etoposide.<sup>164</sup> The investigators found that the addition of radiotherapy resulted in improved median overall survival (17 vs. 11 months). In patients with extensive-stage SCLC who responded to chemotherapy, a

phase 3 trial by Slotman et al (Dutch CREST trial) reported that the addition of sequential thoracic radiotherapy did not improve the primary endpoint of 1-year overall survival (33% vs. 28%,  $P = .066$ ), but a secondary analysis did find improvement in 2-year overall survival (13% vs. 3%,  $P = .004$ ) when compared with patients who did not receive sequential thoracic radiotherapy.<sup>165</sup>

### Prophylactic Cranial Irradiation

Intracranial metastases occur in more than 50% of patients with SCLC. Randomized studies have shown that PCI is effective in decreasing the incidence of cerebral metastases, but most individual studies did not have sufficient power to show a meaningful survival advantage.<sup>166</sup> A meta-analysis of all randomized PCI trials (using data from individual patients) reported a 25% decrease in the 3-year incidence of brain metastases, from 58.6% in the control group to 33.3% in the PCI-treated group.<sup>167</sup> Thus, PCI seems to prevent (and not simply delay) the emergence of brain metastases. This meta-analysis also reported a 5.4% increase in 3-year survival in patients treated with PCI, from 15.3% in the control group to 20.7% in the PCI group.<sup>167</sup> Although the number of patients with extensive-stage disease was small in this meta-analysis, the observed benefit was similar in patients with both limited- and extensive-stage disease.

A retrospective study of patients with limited-stage disease also found that PCI increased survival at 2, 5, and 10 years compared with those who did not receive PCI.<sup>168</sup> A randomized trial from the EORTC assessed PCI versus no PCI in 286 patients with extensive-stage SCLC whose disease had responded to initial chemotherapy; PCI decreased symptomatic brain metastases (14.6% vs. 40.4%) and increased the 1-year survival rate (27.1% vs. 13.3%) compared with controls.<sup>169</sup> Preliminary data from a Japanese phase 3 trial suggest that PCI did not

improve survival in patients with extensive-stage disease who had MRI to confirm that they did not have brain metastases.<sup>170</sup>

Late neurologic sequelae have been attributed to PCI, particularly in studies using fractions greater than 3 Gy and/or administering PCI concurrently with chemotherapy.<sup>171,172</sup> Thus, PCI is not recommended for patients with poor PS (3–4) or impaired neurocognitive function.<sup>173,174</sup> Older age (>60 years) has also been associated with chronic neurotoxicity.<sup>175</sup> When given after the completion of chemotherapy and at a low dose per fraction, PCI may cause less neurologic toxicity.

Before the decision is made to administer PCI, a balanced discussion between the patient and physician is necessary.<sup>176</sup> PCI is a category 1 recommendation for patients with limited-stage disease who attain a complete or partial response; PCI is a category 2A recommendation for patients with extensive-stage disease.<sup>169,173</sup> PCI is also recommended for all patients who have had a complete resection (see *Principles of Surgical Resection* in the NCCN Guidelines for SCLC). The preferred dose for PCI to the whole brain is 25 Gy in 10 daily fractions (2.5 Gy/fraction), (see *Principles of Radiation Therapy* in the NCCN Guidelines for SCLC).<sup>167,169,177</sup> The NCCN Panel feels that a shorter course of PCI may be appropriate (eg, 20 Gy in 5 fractions) for selected patients with extensive-stage disease.<sup>169</sup> Higher doses (eg, 36 Gy) increased mortality and toxicity when compared with standard doses (25 Gy).<sup>175,177</sup> PCI should not be given concurrently with systemic therapy, and high total radiotherapy dose (>30 Gy) should be avoided because of the increased risk of neurotoxicity.<sup>175</sup> Fatigue, headache, and nausea/vomiting are the most common acute toxic effects after PCI.<sup>174,177</sup> After the acute toxicities of initial therapy have resolved, PCI can be administered. For patients not receiving PCI, surveillance for metastases with brain imaging should be considered.

### *Palliative Radiotherapy*

For patients with localized symptomatic sites of disease (ie, painful bony lesions, spinal cord compression, obstructive atelectasis) or with brain metastases, radiotherapy can provide excellent palliation (see *Initial Treatment* in the NCCN Guidelines for SCLC and the NCCN Guidelines for NSCLC, available at [NCCN.org](#)).<sup>178-180</sup> Orthopedic stabilization may be useful in patients at high risk for fracture because of osseous structural impairment. Because patients with SCLC often have a short life span, surgery is not usually recommended for spinal cord compression. Whole-brain radiotherapy is recommended for brain metastases in patients with SCLC due to the frequent occurrence of multiple metastases (see *Principles of Radiation Therapy* in the NCCN Guidelines for SCLC and the NCCN Guidelines for Central Nervous System Cancers, available at [NCCN.org](#)).<sup>181</sup> Although late complications, such as neurocognitive impairment, may occur with whole-brain radiotherapy this is less of an issue in patients with SCLC because long-term survival is rare.<sup>171</sup> The recommended dose for whole-brain radiotherapy is 30 Gy in 10 daily fractions.<sup>181</sup> In patients who develop brain metastases after PCI, stereotactic radiosurgery may be considered.<sup>182</sup>

### ***Surgical Resection of Stage I SCLC***

The *Principles of Surgical Resection* for SCLC are described in the NCCN algorithm; studies supporting these recommendations are described in this section. Briefly, the NCCN Guidelines state that surgery should only be considered for patients with stage I (T1–2, N0) SCLC in whom mediastinal staging has confirmed that mediastinal lymph nodes are not involved.<sup>183</sup> Data show that patients with clinically staged disease in excess of T1–2,N0 do not benefit from surgery.<sup>184</sup> Note that only 5% of patients with SCLC have true stage I SCLC.<sup>39</sup>

The Lung Cancer Study Group conducted the only prospective randomized trial evaluating the role of surgery in SCLC.<sup>184</sup> Patients with limited-stage disease, excluding those with solitary peripheral nodules, received 5 cycles of chemotherapy with CAV; those showing a response to chemotherapy were randomly assigned to undergo resection plus thoracic radiotherapy or thoracic radiotherapy alone. The overall survival rates of patients on the 2 arms were equivalent, suggesting no benefit to surgery in this setting. However, only 19% of enrolled patients had clinical stage I (T1–2, N0, M0) disease.

Most data regarding the benefit of surgery are from retrospective reviews.<sup>183,185-189</sup> These studies report favorable 5-year survival rates of 40% to 60% in patients with stage I disease. In most series, survival rates decline significantly in patients with more advanced disease, leading to the general recommendation that surgery should only be considered in those with stage I disease. Interpretation of these results is limited by the selection bias inherent in retrospective reviews and by the variable use of chemotherapy and radiotherapy.

Analyses of the SEER database also suggest that surgery may be appropriate for some patients with localized disease.<sup>11,190</sup> However, these studies are limited by the lack of information on chemotherapy use in the database. In addition, comparison of the survival of surgical patients to all those who did not undergo surgery is inherently flawed by selection bias. Ultimately, the role of surgery in SCLC will not be fully defined until results are available from trials comparing surgery plus adjuvant chemotherapy to concurrent chemoradiotherapy in patients who are rigorously staged.

### NCCN Guidelines

In all patients with clinical stage I (T1–2, N0) SCLC who are being considered for surgical resection, occult nodal disease should be ruled

out through mediastinal staging before resection.<sup>191</sup> If resection is performed, the NCCN Panel favors lobectomy and does not feel that segmental or wedge resections are appropriate for patients with SCLC. After complete resection, adjuvant chemotherapy or chemoradiation is recommended.<sup>173,187,192,193</sup> Adjuvant chemotherapy alone is recommended for patients without nodal metastases, whereas concurrent chemotherapy and postoperative mediastinal radiotherapy are recommended for patients with nodal metastases (see *Adjuvant Treatment* in the NCCN Guidelines for SCLC). Although panel members agree that postoperative mediastinal radiotherapy is recommended in this setting, it should be based on the extent of nodal sampling/dissection and extent of nodal positivity; however, there are no data to support this recommendation. PCI should be considered after adjuvant therapy in select patients, because it can improve survival (see *Prophylactic Cranial Irradiation* in this Discussion and *Adjuvant Treatment* in the NCCN Guidelines for SCLC).<sup>167</sup> For the 2017 update, the NCCN Panel added new recommendations for response assessment after adjuvant therapy. Response assessment using CT with contrast of the chest, liver, and adrenal gland should occur only after completion of initial therapy for patients with limited-stage disease; repeating scans during therapy is not recommended.

### Surveillance

The schedule for follow-up examinations is shown in the algorithm (see *Surveillance* in the NCCN Guidelines for SCLC); the frequency of surveillance decreases during subsequent years because of the declining risk of recurrence.<sup>194</sup> PET/CT or brain MRI (or CT) is not recommended for routine follow-up. If a new pulmonary nodule develops, it should prompt evaluation for a new primary lung cancer, because second primary tumors are a frequent occurrence in patients who are cured of SCLC.<sup>195,196</sup> Smoking cessation should be encouraged



for all patients with SCLC, because second primary tumors occur less commonly in patients who quit smoking (see the NCCN Guidelines for Smoking Cessation, available at [NCCN.org](#)).<sup>197-199</sup> Former smokers should be encouraged to remain abstinent.

## Lung Neuroendocrine Tumors

LNTs encompass a wide spectrum of disease. Using the 2015 WHO criteria, LNTs are characterized as: 1) high-grade neuroendocrine carcinomas (SCLC and LCNEC); 2) intermediate-grade neuroendocrine carcinomas (atypical carcinoids); or 3) low-grade neuroendocrine carcinomas (typical carcinoids).<sup>18,200-202</sup> SCLC and LCNEC are poorly differentiated tumors that often have a poor prognosis, whereas typical carcinoid is a well-differentiated neuroendocrine tumor that usually has a good prognosis. Atypical carcinoid is a moderately differentiated neuroendocrine cancer and, as such, carries an intermediate prognosis. Although many carcinoids occur in the GI tract (68%), they also occur in the bronchopulmonary system (25%). Carcinoids are rare tumors, but a SEER analysis suggests that their incidence is increasing.<sup>203,204</sup>

## Diagnosis and Staging

Most LNTs are SCLCs, which are managed using the NCCN Guidelines for SCLC. LCNEC is associated with smoking and is managed using the NCCN Guidelines for NSCLC, because the conceptual algorithm used to manage these patients is the same as that for patients with NSCLC.<sup>205-207</sup> However, data suggest that chemotherapy regimens used for SCLC may be a better option for LCNEC if systemic therapy is indicated.<sup>208-212</sup> Low-grade lung neuroendocrine carcinomas (typical carcinoids) and intermediate-grade lung neuroendocrine carcinomas (atypical carcinoids) account for 1% to 2% of lung cancers and are managed using the NCCN Guidelines for Lung Neuroendocrine Tumors. Both histologic and cytologic features can be useful for

distinguishing LNTs from SCLC and LCNEC, although diagnosis can be difficult (see the NCCN Guidelines for Neuroendocrine Tumors and the NCCN Guidelines for NSCLC, available at [NCCN.org](#)).<sup>18,213</sup> CD56, chromogranin, and synaptophysin are useful immunohistochemical markers for identifying neuroendocrine tumors.<sup>18</sup> The proliferative marker Ki-67 may also be useful.<sup>19</sup> Larger surgical specimens are often needed to diagnose atypical carcinoids or LCNEC, which may be difficult to diagnose using small biopsies or cytology.<sup>18</sup>

LNTs are staged using the 7<sup>th</sup> edition of the AJCC staging system for lung tumors (see Tables 2 and 3 in the NCCN Guidelines for SCLC).<sup>41,214</sup> Both low-grade and intermediate-grade LNTs are usually stage I at diagnosis, although lymph node metastases (stages II–III) are more commonly seen in intermediate-grade tumors. Compared with other lung carcinomas, the prognosis is excellent for many patients with low-grade and intermediate-grade LNTs.<sup>18,215</sup>

## Treatment

Surgery is recommended for patients with stage I, II, or IIIA low-grade or intermediate-grade LNTs (ie, typical or atypical carcinoids) (see *Primary Treatment* in the NCCN Guidelines for Lung Neuroendocrine Tumors).<sup>216-218</sup> After surgical resection, 5- and 10-year survival rates are more than 90% for patients with typical carcinoids, whereas 5- and 10-year survival rates are 70% and 50% to 60% for patients with atypical carcinoids.<sup>218-220</sup> Lymph node involvement decreases long-term survival in both typical and atypical carcinoid.<sup>218-220</sup> Recently, the NCCN Panel slightly revised the primary treatment guidelines for patients with stage IIIA LNTs. If surgery is not feasible, cisplatin/etoposide plus radiotherapy is recommended for stage IIIA typical or atypical carcinoids.<sup>221,222</sup> Cisplatin/etoposide plus RT is also recommended for stage IIIB LNTs except for T4 due to multiple lung nodules. Systemic



## NCCN Guidelines Version 2.2017 Small Cell Lung Cancer

therapy (eg, cisplatin/etoposide [preferred for atypical carcinoids], temozolomide ± capecitabine, sunitinib, everolimus) is recommended for patients with unresectable or advanced disease, although response rates are modest and there is no evidence for a preferred regimen for low-grade typical carcinoids.<sup>215,221,223-232</sup> Octreotide (including long-acting release [LAR]) or lanreotide may be considered for select patients with positive octreotide scans or symptoms of carcinoid syndrome.<sup>221,233-235</sup> Surveillance recommendations are also provided in the NCCN Guidelines.

### References

- Howlader N, Noone A, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2013, based on November 2015 SEER data submission, posted to the SEER web site, April 2016. Bethesda, MD: National Cancer Institute; 2016. Available at: [http://seer.cancer.gov/csr/1975\\_2013/](http://seer.cancer.gov/csr/1975_2013/).
- Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. *J Clin Oncol* 2006;24:4539-4544. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17008692>.
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. *CA Cancer J Clin* 2016;66:7-30. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26742998>.
- Pesch B, Kendzia B, Gustavsson P, et al. Cigarette smoking and lung cancer--relative risk estimates for the major histological types from a pooled analysis of case-control studies. *Int J Cancer* 2012;131:1210-1219. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22052329>.
- Antonia SJ, Lopez-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. *Lancet Oncol* 2016;17:883-895. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/27269741>.
- Demetri G, Elias A, Gershenson D, et al. NCCN small-cell lung cancer practice guidelines. *The National Comprehensive Cancer Network. Oncology (Williston Park)* 1996;10:179-194. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/8953602>.
- Jett JR, Schild SE, Kesler KA, Kalemkerian GP. Treatment of small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2013;143:e400S-419S. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23649448>.
- Kalemkerian GP. Advances in the treatment of small-cell lung cancer. *Semin Respir Crit Care Med* 2011;32:94-101. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21500128>.
- Stinchcombe TE, Gore EM. Limited-stage small cell lung cancer: current chemoradiotherapy treatment paradigms. *Oncologist* 2010;15:187-195. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20145192>.
- Demedts IK, Vermaelen KY, van Meerbeeck JP. Treatment of extensive-stage small cell lung carcinoma: current status and future prospects. *Eur Respir J* 2010;35:202-215. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20044461>.
- Yu JB, Decker RH, Detterbeck FC, Wilson LD. Surveillance epidemiology and end results evaluation of the role of surgery for stage I small cell lung cancer. *J Thorac Oncol* 2010;5:215-219. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20101146>.
- Leone FT, Evers-Casey S, Toll BA, Vachani A. Treatment of tobacco use in lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2013;143:e61S-77S. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23649454>.
- Videtic GMM, Stitt LW, Dar AR, et al. Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival. *J Clin Oncol* 2003;21:1544-1549. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12697879>.
- Cuffe S, Moua T, Summerfield R, et al. Characteristics and outcomes of small cell lung cancer patients diagnosed during two lung cancer computed tomographic screening programs in heavy smokers. *J Thorac Oncol* 2011;6:818-822. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21623258>.



15. Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. *N Engl J Med* 2011;365:395-409. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21714641>.
16. Kondo R, Yoshida K, Kawakami S, et al. Different efficacy of CT screening for lung cancer according to histological type: analysis of Japanese-smoker cases detected using a low-dose CT screen. *Lung Cancer* 2011;74:433-440. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21663995>.
17. Rivera MP, Mehta AC, Wahidi MM. Establishing the diagnosis of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2013;143:e142S-165S. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23649436>.
18. Travis WD. Advances in neuroendocrine lung tumors. *Ann Oncol* 2010;21 Suppl 7:vii65-71. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20943645>.
19. Renshaw AA, Haja J, Lozano RL, Wilbur DC. Distinguishing carcinoid tumor from small cell carcinoma of the lung: correlating cytologic features and performance in the College of American Pathologists Non-Gynecologic Cytology Program. *Arch Pathol Lab Med* 2005;129:614-618. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15859631>.
20. Gandhi L, Johnson BE. Paraneoplastic syndromes associated with small cell lung cancer. *J Natl Compr Canc Netw* 2006;4:631-638. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16813730>.
21. Kazarian M, Laird-Offringa IA. Small-cell lung cancer-associated autoantibodies: potential applications to cancer diagnosis, early detection, and therapy. *Mol Cancer* 2011;10:33. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21450098>.
22. Marchioli CC, Graziano SL. Paraneoplastic syndromes associated with small cell lung cancer. *Chest Surg Clin N Am* 1997;7:65-80. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9001756>.
23. Titulaer MJ, Wirtz PW, Willems LN, et al. Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome. *J Clin Oncol* 2008;26:4276-4281. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18779614>.
24. Meriney SD, Hulsizer SC, Lennon VA, Grinnell AD. Lambert-Eaton myasthenic syndrome immunoglobulins react with multiple types of calcium channels in small-cell lung carcinoma. *Ann Neurol* 1996;40:739-749. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8957015>.
25. Graus F, Keime-Guibert F, Rene R, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. *Brain* 2001;124:1138-1148. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11353730>.
26. Delisle L, Boyer MJ, Warr D, et al. Ectopic corticotropin syndrome and small-cell carcinoma of the lung. Clinical features, outcome, and complications. *Arch Intern Med* 1993;153:746-752. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8383484>.
27. Johnson BE, Chute JP, Rushin J, et al. A prospective study of patients with lung cancer and hyponatremia of malignancy. *Am J Respir Crit Care Med* 1997;156:1669-1678. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9372692>.
28. Castillo JJ, Vincent M, Justice E. Diagnosis and management of hyponatremia in cancer patients. *Oncologist* 2012;17:756-765. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22618570>.
29. Schrier RW, Gross P, Gheorghide M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. *N Engl J Med* 2006;355:2099-2112. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17105757>.

30. Verbalis JG, Zeltser D, Smith N, et al. Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: subgroup analysis of a randomized, controlled study. *Clin Endocrinol (Oxf)* 2008;69:159-168. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18034777>.
31. Zakowski MF. Pathology of small cell carcinoma of the lung. *Semin Oncol* 2003;30:3-8. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12635085>.
32. Brenner B, Tang LH, Klimstra DS, Kelsen DP. Small-cell carcinomas of the gastrointestinal tract: a review. *J Clin Oncol* 2004;22:2730-2739. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15226341>.
33. Galanis E, Frytak S, Lloyd RV. Extrapulmonary small cell carcinoma. *Cancer* 1997;79:1729-1736. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9128989>.
34. Guinee DG, Jr., Fishback NF, Koss MN, et al. The spectrum of immunohistochemical staining of small-cell lung carcinoma in specimens from transbronchial and open-lung biopsies. *Am J Clin Pathol* 1994;102:406-414. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7524299>.
35. Kalemkerian GP, Gadgeel SM. Modern staging of small cell lung cancer. *J Natl Compr Canc Netw* 2013;11:99-104. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23307985>.
36. Kalemkerian GP. Staging and imaging of small cell lung cancer. *Cancer Imaging* 2011;11:253-258. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22245990>.
37. Nicholson AG, Chansky K, Crowley J, et al. The International Association for the Study of Lung Cancer lung cancer staging project: proposals for the revision of the clinical and pathologic staging of small cell lung cancer in the forthcoming eighth edition of the TNM classification for lung cancer. *J Thorac Oncol* 2016;11:300-311. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26723244>.
38. Shepherd FA, Crowley J, Van Houtte P, et al. The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. *J Thorac Oncol* 2007;2:1067-1077. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18090577>.
39. Ignatius Ou SH, Zell JA. The applicability of the proposed IASLC staging revisions to small cell lung cancer (SCLC) with comparison to the current UICC 6th TNM Edition. *J Thorac Oncol* 2009;4:300-310. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19156001>.
40. Vallieres E, Shepherd FA, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. *J Thorac Oncol* 2009;4:1049-1059. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19652623>.
41. Edge SB, Byrd DR, Compton CC, et al. *AJCC Cancer Staging Manual*, 7th ed. New York: Springer; 2010.
42. Micke P, Faldum A, Metz T, et al. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer--what limits limited disease? *Lung Cancer* 2002;37:271-276. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12234695>.
43. Podoloff DA, Ball DW, Ben-Josef E, et al. NCCN task force: clinical utility of PET in a variety of tumor types. *J Natl Compr Canc Netw* 2009;7 Suppl 2:S1-26. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19555588>.
44. Bradley JD, Dehdashti F, Mintun MA, et al. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study.

J Clin Oncol 2004;22:3248-3254. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/15310768>.

45. Fischer BM, Mortensen J, Langer SW, et al. A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis. Ann Oncol 2007;18:338-345. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17060487>.

46. Brink I, Schumacher T, Mix M, et al. Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging 2004;31:1614-1620. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15258700>.

47. Kamel EM, Zwahlen D, Wyss MT, et al. Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer. J Nucl Med 2003;44:1911-1917. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14660716>.

48. Rintoul RC, Tournoy KG, El Daly H, et al. EBUS-TBNA for the clarification of PET positive intra-thoracic lymph nodes-an international multi-centre experience. J Thorac Oncol 2009;4:44-48. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19096305>.

49. Medford AR, Bennett JA, Free CM, Agrawal S. Mediastinal staging procedures in lung cancer: EBUS, TBNA and mediastinoscopy. Curr Opin Pulm Med 2009;15:334-342. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19395972>.

50. Foster NR, Mandrekar SJ, Schild SE, et al. Prognostic factors differ by tumor stage for small cell lung cancer: a pooled analysis of North Central Cancer Treatment Group trials. Cancer 2009;115:2721-2731. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19402175>.

51. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol 1990;8:1563-1574. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2167954>.

52. Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992;327:1618-1624. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1331787>.

53. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992;10:890-895. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1316951>.

54. Postmus PE, Haaxma-Reiche H, Gregor A, et al. Brain-only metastases of small cell lung cancer; efficacy of whole brain radiotherapy. An EORTC phase II study. Radiother Oncol 1998;46:29-32. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9488124>.

55. Evans WK, Shepherd FA, Feld R, et al. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol 1985;3:1471-1477. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2997406>.

56. Sundstrom S, Bremnes RM, Kaasa S, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol 2002;20:4665-4672. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12488411>.

57. Kubota K, Hida T, Ishikura S, et al. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study. Lancet Oncol 2014;15:106-113. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24309370>.

58. Saito H, Takada Y, Ichinose Y, et al. Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902. J Clin Oncol 2006;24:5247-5252. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17114657>.



59. Takada M, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. *J Clin Oncol* 2002;20:3054-3060. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12118018>.

60. Bunn PA, Jr., Crowley J, Kelly K, et al. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. *J Clin Oncol* 1995;13:1632-1641. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7602352>.

61. Hatfield LA, Huskamp HA, Lamont EB. Survival and toxicity after cisplatin plus etoposide versus carboplatin plus etoposide for extensive-stage small-cell lung cancer in elderly patients. *J Oncol Pract* 2016;12:666-673. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27352949>.

62. Bishop JF, Raghavan D, Stuart-Harris R, et al. Carboplatin (CBDCA, JM-8) and VP-16-213 in previously untreated patients with small-cell lung cancer. *J Clin Oncol* 1987;5:1574-1578. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2821197>.

63. Skarlos DV, Samantas E, Kosmidis P, et al. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. *Ann Oncol* 1994;5:601-607. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7993835>.

64. Okamoto H, Watanabe K, Kunikane H, et al. Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. *Br J Cancer* 2007;97:162-169. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17579629>.

65. Rossi A, Di Maio M, Chiodini P, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. *J Clin Oncol* 2012;30:1692-1698. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22473169>.

66. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. *N Engl J Med* 2002;346:85-91. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11784874>.

67. Lara PN, Jr., Natale R, Crowley J, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. *J Clin Oncol* 2009;27:2530-2535. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19349543>.

68. Hanna N, Bunn PA, Jr, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer 10.1200/JCO.2005.04.8595. *J Clin Oncol* 2006;24:2038-2043. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16648503>.

69. Hermes A, Bergman B, Bremnes R, et al. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. *J Clin Oncol* 2008;26:4261-4267. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18779613>.

70. Lima JP, dos Santos LV, Sasse EC, et al. Camptothecins compared with etoposide in combination with platinum analog in extensive stage small cell lung cancer: systematic review with meta-analysis. *J Thorac Oncol* 2010;5:1986-1993. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20978445>.

71. Chute JP, Chen T, Feigal E, et al. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. *J Clin Oncol* 1999;17:1794-1801. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10561217>.



72. Niho S, Kubota K, Yoh K, et al. Clinical outcome of chemoradiation therapy in patients with limited-disease small cell lung cancer with ipsilateral pleural effusion. *J Thorac Oncol* 2008;3:723-727. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18594317>.

73. Niho S, Kubota K, Yoh K, et al. Clinical outcome of small cell lung cancer with pericardial effusion but without distant metastasis. *J Thorac Oncol* 2011;6:796-800. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21258253>.

74. Loehrer PJ, Sr., Ansari R, Gonin R, et al. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study. *J Clin Oncol* 1995;13:2594-2599. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7595712>.

75. Pujol JL, Daures JP, Riviere A, et al. Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study. *J Natl Cancer Inst* 2001;93:300-308. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11181777>.

76. Miyamoto H, Nakabayashi T, Isobe H, et al. A phase III comparison of etoposide/cisplatin with or without added ifosfamide in small-cell lung cancer. *Oncology* 1992;49:431-435. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1334539>.

77. Niell HB, Herndon JE, 2nd, Miller AA, et al. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. *J Clin Oncol* 2005;23:3752-3759. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15923572>.

78. Schiller JH, Adak S, Cella D, et al. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group. *J*

*Clin Oncol* 2001;19:2114-2122. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11304763>.

79. Zhou H, Zeng C, Wei Y, et al. Duration of chemotherapy for small cell lung cancer: a meta-analysis. *PLoS One* 2013;8:e73805. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24023692>.

80. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. *Cancer Treat Rep* 1979;63:1727-1733. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/526911>.

81. Fukuoka M, Furuse K, Saijo N, et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. *J Natl Cancer Inst* 1991;83:855-861. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1648142>.

82. Roth BJ, Johnson DH, Einhorn LH, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. *J Clin Oncol* 1992;10:282-291. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1310103>.

83. Miles DW, Earl HM, Souhami RL, et al. Intensive weekly chemotherapy for good-prognosis patients with small-cell lung cancer. *J Clin Oncol* 1991;9:280-285. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1846406>.

84. Murray N, Gelmon K, Shah A. Potential for long-term survival in extensive stage small-cell lung cancer (ESCLC) with CODE chemotherapy and radiotherapy [abstract]. *Lung Cancer* 1994;11 (Suppl 1):99 Abstract 377. Available at:

85. Sculier JP, Paesmans M, Bureau G, et al. Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European Lung



# NCCN Guidelines Version 2.2017

## Small Cell Lung Cancer

Cancer Working Party. J Clin Oncol 1993;11:1858-1865. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8410110>.

86. Souhami RL, Rudd R, Ruiz de Elvira MC, et al. Randomized trial comparing weekly versus 3-week chemotherapy in small-cell lung cancer: a Cancer Research Campaign trial. J Clin Oncol 1994;12:1806-1813. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8083704>.

87. Fukuoka M, Masuda N, Negoro S, et al. CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. Br J Cancer 1997;75:306-309. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9010043>.

88. Murray N, Livingston RB, Shepherd FA, et al. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol 1999;17:2300-2308. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10561291>.

89. Cohen MH, Creaven PJ, Fossieck BE, Jr., et al. Intensive chemotherapy of small cell bronchogenic carcinoma. Cancer Treat Rep 1977;61:349-354. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/194691>.

90. Johnson DH, Einhorn LH, Birch R, et al. A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1987;5:1731-1738. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2824707>.

91. Ihde DC, Mulshine JL, Kramer BS, et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol 1994;12:2022-2034. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7931470>.

92. Arriagada R, Le Chevalier T, Pignon JP, et al. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med 1993;329:1848-1852. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8247036>.

93. Thatcher N, Girling DJ, Hopwood P, et al. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party. J Clin Oncol 2000;18:395-404. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10637255>.

94. Klasa RJ, Murray N, Coldman AJ. Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung. J Clin Oncol 1991;9:499-508. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1847968>.

95. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164-170. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1711156>.

96. Berghmans T, Paesmans M, Lafitte JJ, et al. Role of granulocyte and granulocyte-macrophage colony-stimulating factors in the treatment of small-cell lung cancer: a systematic review of the literature with methodological assessment and meta-analysis. Lung Cancer 2002;37:115-123. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12140132>.

97. Sculier JP, Paesmans M, Lecomte J, et al. A three-arm phase III randomised trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics. Br J Cancer 2001;85:1444-1451. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11720426>.

98. Petrioli R, Roviello G, Laera L, et al. Cisplatin, etoposide, and bevacizumab regimen followed by oral etoposide and bevacizumab maintenance treatment in patients with extensive-stage small cell lung cancer: a single-institution experience. *Clin Lung Cancer* 2015;16:e229-234. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26072097>.
99. Spigel DR, Townley PM, Waterhouse DM, et al. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. *J Clin Oncol* 2011;29:2215-2222. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21502556>.
100. Spigel DR, Greco FA, Zubkus JD, et al. Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer. *J Thorac Oncol* 2009;4:1555-1560. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19875975>.
101. Horn L, Dahlberg SE, Sandler AB, et al. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. *J Clin Oncol* 2009;27:6006-6011. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19826110>.
102. Pujol JL, Lavole A, Quoix E, et al. Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial. *Ann Oncol* 2015;26:908-914. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25688059>.
103. Tiseo M, Boni L, Ambrosio F, et al. Italian multicenter phase III randomized study of cisplatin-etoposide with or without bevacizumab as first-line treatment in extensive stage small cell lung cancer: treatment rationale and protocol design of the GOIRC-AIFA FARM6PMFJM trial. *Clin Lung Cancer* 2015;16:67-70. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25450879>.
104. Reck M, Luft A, Szczesna A, et al. Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. *J Clin Oncol* 2016. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27458307>.
105. Hurria A, Kris MG. Management of lung cancer in older adults. *CA Cancer J Clin* 2003;53:325-341. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15224973>.
106. Corso CD, Rutter CE, Park HS, et al. Role of chemoradiotherapy in elderly patients with limited-stage small-cell lung cancer. *J Clin Oncol* 2015;33:4240-4246. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26481366>.
107. Gridelli C, Casaluca F, Sgambato A, et al. Treatment of limited-stage small cell lung cancer in the elderly, chemotherapy vs. sequential chemoradiotherapy vs. concurrent chemoradiotherapy: that's the question. *Transl Lung Cancer Res* 2016;5:150-154. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27186510>.
108. Girling DJ. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. *Medical Research Council Lung Cancer Working Party. Lancet* 1996;348:563-566. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8774567>.
109. Souhami RL, Spiro SG, Rudd RM, et al. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. *J Natl Cancer Inst* 1997;89:577-580. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9106647>.
110. Neubauer M, Schwartz J, Caracandas J, et al. Results of a phase II study of weekly paclitaxel plus carboplatin in patients with extensive small-cell lung cancer with eastern cooperative oncology group performance status of 2, or age >= 70 years. *J Clin Oncol* 2004;22:1872-1877. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15143079>.
111. Westeel V, Murray N, Gelmon K, et al. New combination of the old drugs for elderly patients with small-cell lung cancer: a phase II study of



# NCCN Guidelines Version 2.2017

## Small Cell Lung Cancer

the PAVE regimen. *J Clin Oncol* 1998;16:1940-1947. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9586913>.

112. Okamoto H, Watanabe K, Nishiwaki Y, et al. Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer. *J Clin Oncol* 1999;17:3540-3545. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10550152>.

113. Matsui K, Masuda N, Yana T, et al. Carboplatin calculated with Chatelut's formula plus etoposide for elderly patients with small-cell lung cancer. *Intern Med* 2001;40:603-606. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11506300>.

114. Murray N, Grafton C, Shah A, et al. Abbreviated treatment for elderly, infirm, or noncompliant patients with limited-stage small-cell lung cancer. *J Clin Oncol* 1998;16:3323-3328. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9779708>.

115. Hurwitz JL, McCoy F, Scullin P, Fennell DA. New advances in the second-line treatment of small cell lung cancer. *Oncologist* 2009;14:986-994. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19819917>.

116. Schneider BJ. Management of recurrent small cell lung cancer. *J Natl Compr Canc Netw* 2008;6:323-331. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18377850>.

117. Owonikoko TK, Behera M, Chen Z, et al. A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer. *J Thorac Oncol* 2012;7:866-872. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22722788>.

118. Postmus PE, Berendsen HH, van Zandwijk N, et al. Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. *Eur J Cancer Clin Oncol* 1987;23:1409-1411. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2824211>.

119. Lammers PE, Shyr Y, Li CI, et al. Phase II study of bendamustine in relapsed chemotherapy sensitive or resistant small-cell lung cancer. *J Thorac Oncol* 2014;9:559-562. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24736081>.

120. Pietanza MC, Kadota K, Huberman K, et al. Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker. *Clin Cancer Res* 2012;18:1138-1145. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22228633>.

121. Cheng S, Evans WK, Stys-Norman D, Shepherd FA. Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline. *J Thorac Oncol* 2007;2:348-354. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17409809>.

122. Masters GA, Declerck L, Blanke C, et al. Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597. *J Clin Oncol* 2003;21:1550-1555. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12697880>.

123. Horn L, Reck M, Spigel DR. The future of immunotherapy in the treatment of small cell lung cancer. *Oncologist* 2016;21:910-921. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27354668>.

124. Zauderer MG, Drilon A, Kadota K, et al. Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase. *Lung Cancer* 2014;86:237-240. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25194640>.

125. Goto K, Ohe Y, Shibata T, et al. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial. *Lancet Oncol* 2016;17:1147-1157. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27312053>.

126. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. *J Clin Oncol* 1999;17:658-667.

Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10080612>.

127. O'Brien ME, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. *J Clin Oncol* 2006;24:5441-5447. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17135646>.

128. Eckardt JR, von Pawel J, Pujol JL, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. *J Clin Oncol* 2007;25:2086-2092. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17513814>.

129. Huber RM, Reck M, Gosse H, et al. Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancer. *Eur Respir J* 2006;27:1183-1189. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/16481389>.

130. Shah C, Ready N, Perry M, et al. A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer. *Lung Cancer* 2007;57:84-88. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17399850>.

131. Shipley DL, Hainsworth JD, Spigel DR, et al. Topotecan: Weekly intravenous (IV) schedule similar to standard 5-day IV schedule as second-line therapy for relapsed small cell lung cancer (SCLC)--A Minnie Pearl Cancer Research Network phase II trial [abstract]. *J Clin Oncol* 2006;24 (Suppl 18):Abstract 7083. Available at:

[http://meeting.ascopubs.org/cgi/content/abstract/24/18\\_suppl/7083](http://meeting.ascopubs.org/cgi/content/abstract/24/18_suppl/7083).

132. Asai N, Ohkuni Y, Matsunuma R, et al. Efficacy and safety of amurubicin for the elderly patients with refractory relapsed small cell lung cancer as third-line chemotherapy. *J Cancer Res Ther* 2012;8:266-271. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22842373>.

133. Ettinger DS, Jotte R, Lorigan P, et al. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. *J Clin Oncol* 2010;28:2598-2603. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/20385980>.

134. Inoue A, Sugawara S, Yamazaki K, et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. *J Clin Oncol* 2008;26:5401-5406. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18854562>.

135. Onoda S, Masuda N, Seto T, et al. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. *J Clin Oncol* 2006;24:5448-5453. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17135647>.

136. Shimokawa T, Shibuya M, Kitamura K, et al. Retrospective analysis of efficacy and safety of amrubicin in refractory and relapsed small-cell lung cancer. *Int J Clin Oncol* 2009;14:63-69. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19225927>.

137. Jotte R, Conkling P, Reynolds C, et al. Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. *J Clin Oncol* 2011;29:287-293. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21135284>.

138. von Pawel J, Jotte R, Spigel DR, et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. *J Clin Oncol* 2014;32:4012-4019. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/25385727>.

139. Kong FM, Lally BE, Chang JY, et al. ACR Appropriateness Criteria(R) radiation therapy for small-cell lung cancer. *Am J Clin Oncol* 2013;36:206-213. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23511336>.

140. Shioyama Y, Nakamura K, Sasaki T, et al. Clinical results of stereotactic body radiotherapy for Stage I small-cell lung cancer: a single institutional experience. *J Radiat Res* 2013;54:108-112. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22923748>.

141. Li C, Xiong Y, Zhou Z, et al. Stereotactic body radiotherapy with concurrent chemotherapy extends survival of patients with limited stage small cell lung cancer: a single-center prospective phase II study. *Med Oncol* 2014;31:369. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25416052>.

142. Murray N, Coy P, Pater JL, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. *J Clin Oncol* 1993;11:336-344. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8381164>.

143. Fried DB, Morris DE, Poole C, et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. *J Clin Oncol* 2004;22:4837-4845. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15570087>.

144. Pijls-Johannesma M, De Ruyscher D, Vansteenkiste J, et al. Timing of chest radiotherapy in patients with limited stage small cell lung cancer: a systematic review and meta-analysis of randomised controlled trials. *Cancer Treat Rev* 2007;33:461-473. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17513057>.

145. De Ruyscher D, Bremer RH, Koppe F, et al. Omission of elective node irradiation on basis of CT-scans in patients with limited disease small cell lung cancer: a phase II trial. *Radiother Oncol* 2006;80:307-312. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16949169>.

146. De Ruyscher D, Lueza B, Le Pechoux C, et al. Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis. *Ann Oncol* 2016. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27436850>.

147. Turrisi AT, 3rd, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. *N Engl J Med* 1999;340:265-271. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9920950>.

148. Komaki R, Paulus R, Ettinger DS, et al. Phase II study of accelerated high-dose radiotherapy with concurrent chemotherapy for patients with limited small-cell lung cancer: Radiation Therapy Oncology Group Protocol 0239. *Int J Radiat Oncol Biol Phys* 2012;83:e531-536. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22560543>.

149. Schild SE, Bonner JA, Shanahan TG, et al. Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. *Int J Radiat Oncol Biol Phys* 2004;59:943-951. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15234027>.

150. Miller KL, Marks LB, Sibley GS, et al. Routine use of approximately 60 Gy once-daily thoracic irradiation for patients with limited-stage small-cell lung cancer. *Int J Radiat Oncol Biol Phys* 2003;56:355-359. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12738309>.

151. Roof KS, Fidias P, Lynch TJ, et al. Radiation dose escalation in limited-stage small-cell lung cancer. *Int J Radiat Oncol Biol Phys* 2003;57:701-708. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14529774>.

152. Bogart JA, Herndon JE, 2nd, Lyss AP, et al. 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808. *Int J Radiat Oncol Biol Phys* 2004;59:460-468. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15145163>.

153. ICRU Report 62: Prescribing, Recording and Reporting Photon Beam Therapy (Supplement to ICRU Report 50). Bethesda, MD: The International Commission on Radiation Units and Measurement (ICRU); 1999. Available at: <http://www.icru.org/home/reports/prescribing-recording-and-reporting-photon-beam-therapy-report-62>.



# NCCN Guidelines Version 2.2017

## Small Cell Lung Cancer

154. ICRU Report 50. Prescribing, Recording and Reporting Photon Beam Therapy. Bethesda, MD: International Commission on Radiation Units and Measurements (ICRU); 1993. Available at: <http://www.icru.org/home/reports/prescribing-recording-and-reporting-photon-beam-therapy-report-50>.

155. Liengswangwong V, Bonner JA, Shaw EG, et al. Limited-stage small-cell lung cancer: patterns of intrathoracic recurrence and the implications for thoracic radiotherapy. *J Clin Oncol* 1994;12:496-502. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8120547>.

156. Kim TH, Cho KH, Pyo HR, et al. Dose-volumetric parameters for predicting severe radiation pneumonitis after three-dimensional conformal radiation therapy for lung cancer. *Radiology* 2005;235:208-215. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15703313>.

157. Rose J, Rodrigues G, Yaremko B, et al. Systematic review of dose-volume parameters in the prediction of esophagitis in thoracic radiotherapy. *Radiother Oncol* 2009;91:282-287. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18950881>.

158. Kong FM, Ritter T, Quint DJ, et al. Consideration of dose limits for organs at risk of thoracic radiotherapy: atlas for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus. *Int J Radiat Oncol Biol Phys* 2011;81:1442-1457. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20934273>.

159. Shirvani SM, Juloori A, Allen PK, et al. Comparison of 2 common radiation therapy techniques for definitive treatment of small cell lung cancer. *Int J Radiat Oncol Biol Phys* 2013;87:139-147. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23920393>.

160. ICRU Report 83: Prescribing, Recording, and Reporting Intensity-Modulated Photon-Beam Therapy. Bethesda, MD: International Commission on Radiation Units and Measurements (ICRU); 2010. Available at: <http://www.icru.org/testing/reports/prescribing-recording-and-reporting-intensity-modulated-photon-beam-therapy-imrt-icru-report-83>.

161. Gregoire V, Mackie TR. State of the art on dose prescription, reporting and recording in intensity-modulated radiation therapy (ICRU report No. 83). *Cancer Radiother* 2011;15:555-559. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21802333>.

162. Hartford AC, Palisca MG, Eichler TJ, et al. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guidelines for intensity-modulated radiation therapy (IMRT). *Int J Radiat Oncol Biol Phys* 2009;73:9-14. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19100920>.

163. Shirvani SM, Komaki R, Heymach JV, et al. Positron emission tomography/computed tomography-guided intensity-modulated radiotherapy for limited-stage small-cell lung cancer. *Int J Radiat Oncol Biol Phys* 2012;82:e91-97. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21489716>.

164. Jeremic B, Shibamoto Y, Nikolic N, et al. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: A randomized study. *J Clin Oncol* 1999;17:2092-2099. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10561263>.

165. Slotman BJ, van Tinteren H, Praag JO, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. *Lancet* 2015;385:36-42. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25230595>.

166. Arriagada R, Le Chevalier T, Borie F, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. *J Natl Cancer Inst* 1995;87:183-190. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7707405>.

167. Auperin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. *N Engl J Med* 1999;341:476-484. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10441603>.

168. Patel S, Macdonald OK, Suntharalingam M. Evaluation of the use of prophylactic cranial irradiation in small cell lung cancer. *Cancer* 2009;115:842-850. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19117355>.

169. Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. *N Engl J Med* 2007;357:664-672. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17699816>.

170. Seto T, Takahashi T, Yamanaka T, et al. Prophylactic cranial irradiation (PCI) has a detrimental effect on the overall survival (OS) of patients (pts) with extensive disease small cell lung cancer (ED-SCLC): Results of a Japanese randomized phase III trial [abstract]. *J Clin Oncol* 2014;32:(Suppl 5):Abstract 7503. Available at:

<http://meetinglibrary.asco.org/content/129034-144>.

171. Le Pechoux C, Laplanche A, Faivre-Finn C, et al. Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01). *Ann Oncol* 2011;22:1154-1163. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21139020>.

172. Slotman BJ, Senan S. Radiotherapy in small-cell lung cancer: lessons learned and future directions. *Int J Radiat Oncol Biol Phys* 2011;79:998-1003. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21353159>.

173. Yang CF, Chan DY, Speicher PJ, et al. Role of adjuvant therapy in a population-based cohort of patients with early-stage small-cell lung cancer. *J Clin Oncol* 2016;34:1057-1064. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/26786925>.

174. Slotman BJ, Mauer ME, Bottomley A, et al. Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms--Results of an international phase III randomized controlled trial by the EORTC

radiation oncology and lung cancer groups. *J Clin Oncol* 2009;27:78-84.

Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19047288>.

175. Wolfson AH, Bae K, Komaki R, et al. Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. *Int J Radiat Oncol Biol Phys* 2011;81:77-84. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/20800380>.

176. Pechoux CL, Sun A, Slotman BJ, et al. Prophylactic cranial irradiation for patients with lung cancer. *Lancet Oncol* 2016;17:e277-293. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27396646>.

177. Le Pechoux C, Dunant A, Senan S, et al. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. *Lancet Oncol* 2009;10:467-474. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19386548>.

178. Maranzano E, Trippa F, Casale M, et al. 8Gy single-dose radiotherapy is effective in metastatic spinal cord compression: results of a phase III randomized multicentre Italian trial. *Radiother Oncol* 2009;93:174-179. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19520448>.

179. Lutz S, Berk L, Chang E, et al. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. *Int J Radiat Oncol Biol Phys* 2011;79:965-976. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21277118>.

180. Ferrell B, Koczywas M, Grannis F, Harrington A. Palliative care in lung cancer. *Surg Clin North Am* 2011;91:403-417, ix. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21419260>.

181. Tsao MN, Lloyd N, Wong RK, et al. Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. *Cochrane Database Syst Rev* 2012;4:CD003869. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22513917>.

182. Wegner RE, Olson AC, Kondziolka D, et al. Stereotactic radiosurgery for patients with brain metastases from small cell lung cancer. *Int J Radiat Oncol Biol Phys* 2011;81:e21-27. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21345622>.

183. Schneider BJ, Saxena A, Downey RJ. Surgery for early-stage small cell lung cancer. *J Natl Compr Canc Netw* 2011;9:1132-1139. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21975913>.

184. Lad T, Piantadosi S, Thomas P, et al. A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. *Chest* 1994;106:320S-323S. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/7988254>.

185. Rostad H, Naalsund A, Jacobsen R, et al. Small cell lung cancer in Norway. Should more patients have been offered surgical therapy? *Eur J Cardiothorac Surg* 2004;26:782-786. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/15450573>.

186. Inoue M, Miyoshi S, Yasumitsu T, et al. Surgical results for small cell lung cancer based on the new TNM staging system. Thoracic Surgery Study Group of Osaka University, Osaka, Japan. *Ann Thorac Surg* 2000;70:1615-1619. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/11093496>.

187. Brock MV, Hooker CM, Syphard JE, et al. Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: Its time has come. *J Thorac Cardiovasc Surg* 2005;129:64-72. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/15632826>.

188. Lim E, Belcher E, Yap YK, et al. The role of surgery in the treatment of limited disease small cell lung cancer: time to reevaluate. *J Thorac Oncol* 2008;3:1267-1271. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18978561>.

189. Shields TW, Higgins GA, Jr., Matthews MJ, Keehn RJ. Surgical resection in the management of small cell carcinoma of the lung. *J Thorac Cardiovasc Surg* 1982;84:481-488. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/6289013>.

190. Schreiber D, Rineer J, Weedon J, et al. Survival outcomes with the use of surgery in limited-stage small cell lung cancer: should its role be re-evaluated? *Cancer* 2010;116:1350-1357. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/20082453>.

191. Inoue M, Nakagawa K, Fujiwara K, et al. Results of preoperative mediastinoscopy for small cell lung cancer. *Ann Thorac Surg* 2000;70:1620-1623. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/11093497>.

192. Shepherd FA, Evans WK, Feld R, et al. Adjuvant chemotherapy following surgical resection for small-cell carcinoma of the lung. *J Clin Oncol* 1988;6:832-838. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/2835443>.

193. Tsuchiya R, Suzuki K, Ichinose Y, et al. Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: the Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101). *J Thorac Cardiovasc Surg* 2005;129:977-983. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/15867769>.

194. Manapov F, Klocking S, Niyazi M, et al. Timing of failure in limited disease (stage I-III) small-cell lung cancer patients treated with chemoradiotherapy: a retrospective analysis. *Tumori* 2013;99:656-660. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/24503787>.

195. Johnson BE, Linnoila RI, Williams JP, et al. Risk of second aerodigestive cancers increases in patients who survive free of small-cell lung cancer for more than 2 years. *J Clin Oncol* 1995;13:101-111. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7799009>.

196. Johnson BE. Second lung cancers in patients after treatment for an initial lung cancer. *J Natl Cancer Inst* 1998;90:1335-1345. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9747865>.

197. Richardson GE, Tucker MA, Venzon DJ, et al. Smoking cessation after successful treatment of small-cell lung cancer is associated with fewer smoking-related second primary cancers. *Ann Intern Med* 1993;119:383-390. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8393311>.

198. Kawahara M, Ushijima S, Kamimori T, et al. Second primary tumours in more than 2-year disease-free survivors of small-cell lung cancer in Japan: the role of smoking cessation. *Br J Cancer* 1998;78:409-412. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9703291>.

199. Parsons A, Daley A, Begh R, Aveyard P. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. *BMJ* 2010;340:b5569. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20093278>.

200. Travis W, Brambilla E, Burke A, et al. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. Fourth edition. Geneva, Switzerland: World Health Organization; 2015.

201. Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. *J Thorac Oncol* 2015;10:1243-1260. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26291008>.

202. Fisseler-Eckhoff A, Demes M. Neuroendocrine tumors of the lung. *Cancers (Basel)* 2012;4:777-798. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24213466>.

203. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. *J Clin Oncol* 2008;26:3063-3072. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18565894>.

204. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. *Cancer* 2003;97:934-959. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12569593>.

205. Grand B, Cazes A, Mordant P, et al. High grade neuroendocrine lung tumors: Pathological characteristics, surgical management and prognostic implications. *Lung Cancer* 2013;81:404-409. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23769675>.

206. Kalemkerian GP. Pulmonary neuroendocrine carcinomas: progress and pitfalls. *J Natl Compr Canc Netw* 2011;9:1081-1082. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21975910>.

207. Varlotto JM, Medford-Davis LN, Recht A, et al. Should large cell neuroendocrine lung carcinoma be classified and treated as a small cell lung cancer or with other large cell carcinomas? *J Thorac Oncol* 2011;6:1050-1058. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21566535>.

208. Niho S, Kenmotsu H, Sekine I, et al. Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study. *J Thorac Oncol* 2013;8:980-984. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23774385>.

209. Rossi G, Cavazza A, Marchioni A, et al. Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung. *J Clin Oncol*



2005;23:8774-8785. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/16314638>.

210. Sun JM, Ahn MJ, Ahn JS, et al. Chemotherapy for pulmonary large cell neuroendocrine carcinoma: similar to that for small cell lung cancer or non-small cell lung cancer? *Lung Cancer* 2012;77:365-370. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22579297>.

211. Iyoda A, Makino T, Koezuka S, et al. Treatment options for patients with large cell neuroendocrine carcinoma of the lung. *Gen Thorac Cardiovasc Surg* 2014;62:351-356. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24719260>.

212. Le Treut J, Sault MC, Lena H, et al. Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study. *Ann Oncol* 2013;24:1548-1552. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23406729>.

213. den Bakker MA, Thunnissen FB. Neuroendocrine tumours--challenges in the diagnosis and classification of pulmonary neuroendocrine tumours. *J Clin Pathol* 2013;66:862-869. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23685279>.

214. Travis WD, Giroux DJ, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM Classification for Lung Cancer. *J Thorac Oncol* 2008;3:1213-1223. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18978555>.

215. Pusceddu S, Catena L, Valente M, et al. Long-term follow up of patients affected by pulmonary carcinoid at the Istituto Nazionale Tumori of Milan: a retrospective analysis. *J Thorac Dis* 2010;2:16-20. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22263011>.

216. Wolin EM. Challenges in the diagnosis and management of well-differentiated neuroendocrine tumors of the lung (typical and atypical carcinoid): current status and future considerations. *Oncologist*

2015;20:1123-1131. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/26306904>.

217. Kyriss T, Maier S, Veit S, et al. Carcinoid lung tumors: long-term results from 111 resections. *Thorac Surg Sci* 2006;3:Doc03. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21289951>.

218. Rea F, Rizzardi G, Zuin A, et al. Outcome and surgical strategy in bronchial carcinoid tumors: single institution experience with 252 patients. *Eur J Cardiothorac Surg* 2007;31:186-191. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17140801>.

219. Detterbeck FC. Management of carcinoid tumors. *Ann Thorac Surg* 2010;89:998-1005. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20172187>.

220. Cardillo G, Sera F, Di Martino M, et al. Bronchial carcinoid tumors: nodal status and long-term survival after resection. *Ann Thorac Surg* 2004;77:1781-1785. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15111186>.

221. Chong CR, Wirth LJ, Nishino M, et al. Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors. *Lung Cancer* 2014;86:241-246. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25218177>.

222. Wirth LJ, Carter MR, Janne PA, Johnson BE. Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy. *Lung Cancer* 2004;44:213-220. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15084386>.

223. Faggiano A, Malandrino P, Modica R, et al. Efficacy and safety of everolimus in extrapancreatic neuroendocrine tumor: a comprehensive review of literature. *Oncologist* 2016;21:875-886. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27053503>.

224. Forde PM, Hooker CM, Boikos SA, et al. Systemic therapy, clinical outcomes, and overall survival in locally advanced or metastatic



pulmonary carcinoid: a brief report. *J Thorac Oncol* 2014;9:414-418.

Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24518093>.

225. Fine RL, Gulati AP, Krantz BA, et al. Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience. *Cancer Chemother Pharmacol* 2013;71:663-670. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23370660>.

226. Fazio N, Granberg D, Grossman A, et al. Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study. *Chest* 2013;143:955-962. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23187897>.

227. Jett JR, Carr LL. Systemic treatment of advanced lung carcinoid tumors: show me the data! *Chest* 2013;143:884-886. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23546476>.

228. Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. *J Clin Oncol* 2008;26:4311-4318. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18779618>.

229. Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. *Cancer* 1991;68:227-232. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1712661>.

230. Ekeblad S, Sundin A, Janson ET, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. *Clin Cancer Res* 2007;13:2986-2991. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17505000>.

231. Kulke MH, Hornick JL, Frauenhoffer C, et al. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-

based therapy in patients with neuroendocrine tumors. *Clin Cancer Res* 2009;15:338-345. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19118063>.

232. Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. *J Clin Oncol* 2008;26:3403-3410. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18612155>.

233. Caplin ME, Pavel M, Cwikla JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. *N Engl J Med* 2014;371:224-233. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25014687>.

234. Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. *J Clin Oncol* 2009;27:4656-4663. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19704057>.

235. Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. *Lancet* 2011;378:2005-2012. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22119496>.